Document

0001628280-17-010010.txt : 20171020 0001628280-17-010010.hdr.sgml : 20171020 20171020160611 ACCESSION NUMBER: 0001628280-17-010010 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171020 DATE AS OF CHANGE: 20171020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroMetrix, Inc. CENTRAL INDEX KEY: 0001289850 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043308180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33351 FILM NUMBER: 171147101 BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 890-9989 MAIL ADDRESS: STREET 1: 1000 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 a10q9302017document.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number 001-33351

_________________________________________________

NEUROMETRIX, INC.

(Exact name of registrant as specified in its charter)



Delaware	04-3308180
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

1000 Winter Street, Waltham, Massachusetts	02451
(Address of principal executive offices)	(Zip Code)

(781) 890-9989

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):



Large accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company x
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Yes ¨ No x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 2,345,519 shares of common stock, par value $0.0001 per share, were outstanding as of October 13, 2017.

In addition, there were 454,781 warrants to purchase shares of the issuer's common stock listed under NUROW on the NASDAQ stock exchange outstanding as of October 13, 2017.

NeuroMetrix, Inc.

Form 10-Q

Quarterly Period Ended September 30, 2017

TABLE OF CONTENTS



PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements:

	Balance Sheets (unaudited) as of September 30, 2017 and December 31, 2016	4

	Statements of Operations (unaudited) for the Quarters and Nine Months Ended September 30, 2017 and 2016	5

	Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2017 and 2016	6

	Notes to Unaudited Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4.	Controls and Procedures	25

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	26

Item 1A.	Risk Factors	26

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3.	Defaults Upon Senior Securities	26

Item 4.	Mine Safety Disclosures	26

Item 5.	Other Information	26

Item 6.	Exhibits	26

Signatures		27

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

NeuroMetrix, Inc.

Balance Sheets



	September 30, 2017			December 31, 2016
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	3,969,218		$	3,949,135
Accounts receivable, net	423,444			738,729
Inventories	1,786,074			1,252,238
Prepaid expenses and other current assets	2,041,935			1,646,821
Total current assets	8,220,671			7,586,923

Fixed assets, net	417,290			532,706
Other long-term assets	134,695			164,262
Total assets	$	8,772,656		$	8,283,891

Liabilities and Stockholders’ Equity
Current liabilities:

Accounts payable	$	725,224		$	734,048
Accrued compensation	692,937			307,471
Accrued expenses	1,911,062			1,648,731
Deferred revenue	925,794			628,236
Total current liabilities	4,255,017			3,318,486

Common stock warrants	—			4,641
Total liabilities	4,255,017			3,323,127

Commitments and contingencies (Note 8)

Stockholders’ equity:
Preferred stock	—			—
Convertible preferred stock	27			18
Common stock, $0.0001 par value; 100,000,000 shares authorized at September 30, 2017 and December 31, 2016; 2,145,519 and 836,862 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	215			84
Additional paid-in capital	192,975,377			183,439,463
Accumulated deficit	(188,457,980		)	(178,478,801		)
Total stockholders’ equity	4,517,639			4,960,764
Total liabilities and stockholders’ equity	$	8,772,656		$	8,283,891

The accompanying notes are an integral part of these interim financial statements.

NeuroMetrix, Inc.

Statements of Operations

(Unaudited)



	Quarters Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016

Revenues	$	3,546,680		$	3,389,427		$	12,162,861		$	8,312,096

Cost of revenues	2,040,997			2,031,823			7,378,001			5,086,706

Gross profit	1,505,683			1,357,604			4,784,860			3,225,390

Operating expenses:
Research and development	840,577			1,202,651			2,621,445			3,487,291
Sales and marketing	2,919,504			2,959,311			8,436,497			8,199,469
General and administrative	1,258,466			1,165,815			3,925,595			3,882,461

Total operating expenses	5,018,547			5,327,777			14,983,537			15,569,221

Loss from operations	(3,512,864		)	(3,970,173		)	(10,198,677		)	(12,343,831		)

Interest income	3,554			5,772			11,018			17,030
Change in fair value of warrant liability	327			56,248			208,480			227,873

Net loss	(3,508,983		)	(3,908,153		)	(9,979,179		)	(12,098,928		)

Net loss applicable to common stockholders:

Deemed dividends attributable to preferred shareholders (Note 9)	(2,833,098		)	—			(6,874,780		)	(19,846,377		)

Net loss applicable to common stockholders	$	(6,342,081	)	$	(3,908,153	)	$	(16,853,959	)	$	(31,945,305	)
Net loss per common share applicable to common stockholders, basic and diluted	$	(3.11	)	$	(6.11	)	$	(11.62	)	$	(56.09	)

Weighted average number of common shares outstanding, basic and diluted	2,036,117			639,512			1,450,237			569,555

The accompanying notes are an integral part of these interim financial statements.

NeuroMetrix, Inc.

Statements of Cash Flows

(Unaudited)



	Nine Months Ended September 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(9,979,179	)	$	(12,098,928	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	198,892			189,224
Stock-based compensation	170,093			176,684
Change in fair value of warrant liability	(208,480		)	(227,873		)
Changes in operating assets and liabilities:
Accounts receivable	315,285			236,447
Inventories	(533,836		)	(73,072		)
Prepaid expenses and other current and long-term assets	(365,547		)	(408,532		)
Accounts payable	(22,074		)	(287,427		)
Accrued expenses and compensation	647,797			634,181
Deferred revenue	297,558			402,178
Net cash used in operating activities	(9,479,491		)	(11,457,118		)

Cash flows from investing activities:
Purchases of fixed assets	(70,226		)	(87,884		)
Net cash used in investing activities	(70,226		)	(87,884		)

Cash flows from financing activities:
Net proceeds from issuance of stock and warrants	9,569,800			6,650,316
Net cash provided by financing activities	9,569,800			6,650,316

Net increase/(decrease) in cash and cash equivalents	20,083			(4,894,686		)
Cash and cash equivalents, beginning of period	3,949,135			12,462,872
Cash and cash equivalents, end of period	$	3,969,218		$	7,568,186
Supplemental disclosure of cash flow information:
Change in fair value of warrant liability from repricing	$	244,611		$	—
Exchange of warrant liability for Series F Preferred Stock	$	40,772		$	—
Common stock issued to settle employee incentive compensation obligation	$	—		$	318,761

The accompanying notes are an integral part of these interim financial statements.

NeuroMetrix, Inc.

Notes to Unaudited Financial Statements

September 30, 2017


1.	Business and Basis of Presentation

Our Business-An Overview

NeuroMetrix, Inc. or the Company, is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The Company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The Company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The Company maintains an active research effort and has several pipeline programs. The Company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996.

During the first nine months of 2017, the Company completed two equity offerings, detailed in Note 9 to the financial statements, with anticipated gross proceeds of $14.0 million and anticipated net proceeds of approximately $12.9 million after deducting fees and expenses. Gross proceeds of $3.5 million from the second tranche of the Q3 2017 Offering are expected to be received by the Company in October of 2017.

The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses from operations and negative cash flows from operating activities. At September 30, 2017, the Company had an accumulated deficit of $188.5 million. The Company held cash and cash equivalents of $4.0 million as of September 30, 2017. The Company believes that these resources, cash proceeds from the second 2017 equity offering, and the cash to be generated from expected product sales will be sufficient to meet its projected operating requirements into the second quarter of 2018. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products and the uncertainty of future revenues; (b) changes the Company may make to the business that affect ongoing operating expenses; (c) changes the Company may make in its business strategy; (d) regulatory developments or inquiries affecting the Company’s existing products and products under development; (e) changes the Company may make in its research and development spending plans; and (f) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company will need to raise additional funds to support its operating and capital needs in the second quarter of 2018 and beyond. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company intends to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected.

Certain prior period amounts have been adjusted to reflect the Company's 1-for-8 reverse stock split effected May 11, 2017.

Unaudited Interim Financial Statements

The accompanying unaudited balance sheet as of September 30, 2017, unaudited statements of operations for the quarters and nine months ended September 30, 2017 and 2016 and the unaudited statements of cash flows for the nine months ended September 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2016 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair statement of the Company’s financial position and operating results. Operating results for the quarters and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on February 9, 2017 (File No. 001-33351), or the Company’s 2016 Form 10-K.

Revenues

The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured. Revenues associated with the Company’s medical devices and consumables are generally recognized upon shipment, assuming all other revenue recognition criteria have been met. Revenue associated with shipments made to distributors who have the right to return any unsold product is recognized once the product is sold by the distributor to the end customer (i.e. under a sell-through model), assuming all other revenue recognition criteria have been met. Cash received prior to all the conditions for revenue recognition being met is recorded as deferred revenue. Deferred revenue recorded prior to cash receipt is recorded as an offset to accounts receivable.

As of September 30, 2017 the total value of shipments made to sell-through distributors but not yet sold through to end customers totaled $2,272,736. Of this total, $1,346,942 was recorded as a reduction to accounts receivable and $925,794 was recorded in deferred revenue, as cash had been received. As of December 31, 2016, the total value of shipments that had been made to sell-through distributors but had not yet been sold through to end customers totaled $1,247,545. Of this total, $619,309 was recorded as a reduction to accounts receivable and $628,236 was recorded in deferred revenue, as cash had been received. Related costs of goods sold of $1,466,230 and $910,595 have been deferred and recorded in prepaid expenses and other current assets as of September 30, 2017 and December 31, 2016, respectively.

Revenue recognition involves judgments, including assessments of expected returns from customers who have the right to return product for any reason under 30 days or 60 days rights of return. Where the Company can reasonably estimate future returns, it recognizes revenues and records as a reduction of revenue a provision for estimated returns. The Company analyzes various factors, including its historical product returns in arriving at this judgment. Changes in judgments or estimates could materially impact the timing and amount of revenues and costs recognized. The provision for expected returns recorded in accrued expense was $454,730 and $488,200 as of September 30, 2017 and December 31, 2016, respectively.

Accounts receivable are recorded net of the allowance for doubtful accounts which represents the Company’s best estimate of probable credit losses. Allowance for doubtful accounts was $25,000 as of September 30, 2017 and December 31, 2016.

One customer accounted for 21% and 18% of total revenue for the quarter and nine months ended September 30, 2017, respectively. A different customer accounted for approximately 11% of total revenue for nine-months ended September 30, 2016. Customers individually accounting for greater than 10% of accounts receivables totaled 28% and 41% of accounts receivables as of September 30, 2017 and December 31, 2016, respectively.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2016-2, Leases (Topic 842) (“ASU 2016-2”). ASU 2016-2 requires that lessees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. The provisions of this guidance are effective for annual periods beginning after December 31, 2018, and for interim periods therein. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2016-2 will have on the Company’s financial statements and which adoption method will be used.

In May 2014, the FASB and the International Accounting Standards Board (“IASB”) jointly issued Accounting Standards Update (“ASU”) No. 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”), a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance. The objective of ASU 2014-9 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. An entity can elect to adopt ASU 2014-9 using one of two methods, either full retrospective adoption to each prior reporting period, or recognizing the cumulative effect of adoption at the date of initial application. In March 2016, the FASB issued ASU No. 2016-8, Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net), which clarifies the implementation guidance on principal versus agent considerations. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2014-9 will have on the Company’s financial statements.


2.	Comprehensive Loss

For the quarters and nine months ended September 30, 2017 and 2016, the Company had no components of other comprehensive income or loss other than net loss itself.


3.	Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period plus the dilutive effect of the weighted average number of outstanding instruments such as options, warrants, and restricted stock. Because the Company has reported a net loss for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, in calculating net loss per share amounts, shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:



	Quarters Ended September 30,		Nine Months Ended September 30,
	2017	2016	2017	2016
Options	100,237	58,663	98,642	37,709
Warrants	1,206,504	3,525,872	3,469,612	2,621,450
Convertible preferred stock	6,422,034	1,386,888	4,328,089	984,127
Total	7,728,775	4,971,423	7,896,343	3,643,286


4.	Inventories

Inventories consist of the following:



	September 30, 2017		December 31, 2016
Purchased components	$	914,150	$	466,906
Work in progress	91,335		154,971
Finished goods	780,589		630,361
	$	1,786,074	$	1,252,238


5.	Accrued Expenses

Accrued expenses consist of the following:



	September 30, 2017		December 31, 2016

Sales return allowance	$	454,730	$	488,200
Technology fees	450,000		450,000
Professional services	343,000		390,800
Advertising and promotion	335,600		28,100
Warranty reserve	112,008		45,879
Other	215,724		245,752
	$	1,911,062	$	1,648,731


6.	Commitments and Contingencies

Operating Lease

In August 2014, the Company entered into a 5-year operating lease agreement with one 5-year extension option for manufacturing and order fulfillment facilities in Woburn, Massachusetts (the “Woburn Lease”). The Woburn Lease commenced December 15, 2014 and has a monthly base rent of $7,598. In September 2014, the Company entered into a 7-year operating lease agreement with one 5-year extension option for its corporate office and product development activities in Waltham, Massachusetts (the “Waltham Lease”). The term of the Waltham Lease commenced on February 20, 2015 and includes fixed payment obligations that escalate over the initial lease term. Average monthly base rent under the 7-year lease is approximately $37,792. These payment obligations were accrued and recognized over the term of occupancy. Under the Waltham Lease, the landlord was responsible for making certain improvements to the leased space at an agreed upon cost to the landlord. Total costs for the landlord improvements exceeded the agreed upon cost by $275,961. The landlord billed that excess cost to the Company as additional rent which has been included in other long term assets at September 30, 2017. This additional rent has been included in the net calculation of lease payments, so that rent expense is recognized on a straight-line basis over the term of occupancy.


7.	Fair Value Measurements

The Fair Value Measurements and Disclosures Topic of the Codification defines fair value, establishes a framework for measuring fair value in applying generally accepted accounting principles, and expands disclosures about fair value measurements. This Codification topic identifies two kinds of inputs that are used to determine the fair value of assets and liabilities: observable and unobservable. Observable inputs are based on market data or independent sources while unobservable inputs are based on the Company’s own market assumptions. Once inputs have been characterized, this Codification topic requires companies to prioritize the inputs used to measure fair value into one of three broad levels. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values identified by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values identified by Level 3 inputs are unobservable data points and are used to measure fair value to the extent that observable inputs are not available. Unobservable inputs reflect the Company’s own assumptions about the assumptions that market participants would use at pricing the asset or liability.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.



			Fair Value Measurements at September 30, 2017 Using
	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	197,370	$	197,370	$	—	$	—
Total	$	197,370	$	197,370	$	—	$	—

The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities, which relate to warrants issued by the Company in offerings in 2013 and 2014, between December 31, 2016 and September 30, 2017.



	2014 Offering			2013 Offering			Total
Balance at December 31, 2016	$	4,112		$	529		$	4,641
Change in fair value of warrant liability from repricing (see Note 9)	177,999			66,612			244,611
Change in fair value of warrant liability	(147,278		)	(61,202		)	(208,480		)
Repurchase and retirement of warrants (see Note 9)	(34,833		)	(5,939		)	(40,772		)
Balance at September 30, 2017	$	—		$	—		$	—



			Fair Value Measurements at December 31, 2016 Using
	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	833,831	$	833,831	$	—	$	—
Total	$	833,831	$	833,831	$	—	$	—

Liabilities:
Common stock warrants	$	4,641	$	—	$	—	$	4,641
Total	$	4,641	$	—	$	—	$	4,641

Due to the lack of market quotes relating to our common stock warrants then outstanding, the fair value of the common stock warrants was determined at December 31, 2016 using the Black-Scholes model, which is based on Level 3 inputs. As of December 31, 2016, inputs used in the Black-Scholes model are presented below. The assumptions used may change as the underlying sources of these assumptions and market conditions change. Based on the Black-Scholes model, the Company recorded a common stock warrants liability of $4,641 at December 31, 2016.



	Black-Scholes Inputs to Warrant Liability Valuation at December 31, 2016
Warrants:	Stock Price		Exercise Price		Expected Volatility		Risk-Free Interest		Expected Term	Dividends
2014 Offering	$	5.92	$	65.28	64.19	%	1.33	%	2 years, 6 months	none
2013 Offering	$	5.92	$	64.00	71.61	%	0.99	%	1 year, 5 months	none


8.	Credit Facility

The Company is party to a Loan and Security Agreement, as amended (the “Credit Facility”), with a bank. As of September 30, 2017, the Credit Facility permitted the Company to borrow up to $2.5 million on a revolving basis. The Credit Facility was amended most recently on December 29, 2016, and expires on January 15, 2018. Amounts borrowed under the Credit Facility will bear interest equal to the prime rate plus 0.5%. Any borrowings under the Credit Facility will be collateralized by the Company’s cash, accounts receivable, inventory, and equipment. The Credit Facility includes traditional lending and reporting covenants. These include certain financial covenants applicable to liquidity that are to be maintained by the Company. As of September 30, 2017, the Company was in compliance with these covenants and had not borrowed any funds under the Credit Facility. However, $226,731 of the amount under the Credit Facility is restricted to support letters of credit issued in favor of the Company's facilities landlords. Consequently, the amount available for borrowing under the Credit Facility as of September 30, 2017 was approximately $2.3 million.


9.	Stockholders’ Equity

Preferred stock and convertible preferred stock consist of the following:



	September 30, 2017		December 31, 2016
Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2017 and December 31, 2016; no shares issued and outstanding at September 30, 2017 and December 31, 2016	$	—	$	—
Series B convertible preferred stock, $0.001 par value, 147,000 shares designated at September 30, 2017 and December 31, 2016, and 500 shares issued and outstanding at September 30, 2017 and December 31, 2016	$	1	$	1
Series D convertible preferred stock, $0.001 par value, 21,300 shares designated at September 30, 2017 and December 31, 2016, 14,052.93 and 17,202.65 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	14	$	17
Series E convertible preferred stock, $0.001 par value, 7,000 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 7,000 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	7	$	—
Series F convertible preferred stock, $0.001 par value, 10,621 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 5,819.15 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	5	$	—

Private Offerings of Common Stock and Warrants

2017 activity

In the third quarter of 2017, the Company entered into agreements with respect to a private equity offering (the “Q3 2017 Offering”) with an institutional investor and its affiliates (collectively the “Investor”). The Q3 2017 Offering is structured in two tranches. The first tranche, which closed in July 2017, issued (i) 3,500 shares of Series F convertible preferred stock (the “Series F Preferred Stock”) at a price of $1,000 per share and (ii) 3,621 shares of Series F Preferred Stock in exchange for the repurchase and retirement of 4,184,483 warrants to purchase common stock valued by an independent party at $3,622,219. The second tranche, which is expected to close in October 2017, will issue (i) 3,500 shares of Series F Preferred Stock at a price of $1,000 per share. The Q3 2017 Offering also reset the conversion price of 14,052.93 shares of Series D convertible preferred stock and 7,000 shares of Series E convertible preferred stock that were held by the Investor to $2.63 per share. The first tranche of the Q3 2017 Offering resulted in gross proceeds of $3.5 million, and after deducting fees and expenses, net proceeds were $3.3 million.

In the first quarter of 2017, the Company completed a private equity offering (the “Q1 2017 Offering”) with the Investor and issued (i) 7,000 shares of Series E convertible preferred stock (the “Series E Preferred Stock”) at a price of $1,000 per share, and (ii) warrants to purchase up to 1,250,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), at an exercise price of $5.60 per share. As a part of this offering, the Company reset (i) the conversion price of 19,458.90 shares of Series D convertible preferred stock that were held by the Investor to $5.60 per share, and (ii) the exercise price of warrants to purchase up to 2,934,484 shares of Common Stock that were held by the Investor to $5.60 per share. The Q1 2017 Offering resulted in gross proceeds of $7.0 million, and after deducting fees and expenses, net proceeds were $6.3 million.

Each share of Series D Preferred Stock, Series E Preferred Stock, and Series F Preferred Stock (collectively the "Preferred Stock") have a stated value of $1,000 and is convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value by the conversion price of $2.63, which is subject to adjustment as provided in the Certificate of Designation for the Preferred Stock. The Preferred Stock has no dividend rights, liquidation preference or other preferences over Common Stock and has no voting rights except as provided in the Certificate of Designation for the Preferred Stock and as required by law.

The Q3 2017 Offering and the Q1 2017 Offering were accounted for as extinguishments of the Investor’s equity holdings in recognition of the revisions of certain preexisting equity instruments and the significant transfer of value in excess of the funding received by the Company. Under the extinguishment model, a deemed dividend was recognized within additional paid in capital which represented the fair value of issued Preferred Stock plus the incremental fair value of repricing the Preferred Stock held by the Investor, less the fair value of the consideration transferred, less the carrying value of the outstanding

Preferred Stock, and warrants to purchase Common Stock. The amount of the deemed dividend totaled $2.8 million and $4.0 million for the Q3 2017 Offering and the Q1 2017 Offering, respectively.

The Company determined that equity classification was appropriate for the warrants issued in the Q1 2017 Offering, following guidance in the Derivatives and Hedging topic of the Codification. In making this equity classification determination, the Company noted the warrants may only be settled in shares of common stock and had no requirements to be settled in registered shares when exercised. The fair value of the five year warrants was estimated to be $3.49 million on the offering date using a Black-Scholes model with the following assumptions: stock price of $4.96, exercise price of $5.60, expected volatility of 70.2%, risk free interest rate of 2.04%, expected term of five years, and no dividends.

2016 activity

In June 2016, the Company completed a private equity offering with one institutional investor (the “Investor”) and issued (i) 21,300 shares of Series D convertible preferred stock (the “Series D Preferred Stock”) at a price of $1,000 per share, and (ii) warrants to purchase up to 1,475,069 shares of common stock, par value $0.0001 per share (the “Common Stock”), at an exercise price of $13.52 per share (the “June 2016 Offering”). As a part of this offering, the Company redeemed 13,800 shares of Series C convertible preferred stock (the “Series C Preferred Stock”) issued in December 2015 that were held by the Investor. Accordingly, the June 2016 Offering resulted in proceeds of $7.5 million. After underwriting discounts, commission and expenses, net proceeds of the June 2016 Offering were $6.7 million.

The June 2016 Offering was accounted for as a modification of the Investor’s Series C Preferred Stock. Under the modification model, a deemed dividend was recognized within additional paid in capital which represented the fair value of consideration transferred plus the fair value of repurchased Series C Preferred Stock, less the fair value of the newly issued Series D Preferred Stock and warrants. The amount of the deemed dividend totaled $19.8 million.

Other equity activity

During the nine months ended September 30, 2017, 3,149.72 shares of the Series D Preferred Stock were converted into a total of 809,103 shares of Common Stock. As of September 30, 2017, 14,052.93 shares of Series D Preferred Stock remained outstanding.

During the nine months ended September 30, 2017, 1,301.85 shares of the Series F Preferred Stock were converted into a total of 495,000 shares of Common Stock. As of September 30, 2017, 5,819.15 shares of Series F Preferred Stock remained outstanding.

Total compensation cost related to nonvested awards not yet recognized at September 30, 2017 was $418,881. The total compensation costs are expected to be recognized over a weighted-average period of 2.6 years.


10.	Reverse Stock Split

On May 11, 2017, the Company effected a 1-for-8 reverse stock split of its Common Stock, or the Reverse Stock Split. The par value and other terms of the common stock were not affected by the Reverse Stock Split. The Company’s shares outstanding immediately prior to the split totaled 10,147,721, which were subsequently adjusted to 1,268,440 shares outstanding. Share, per share, and stock option amounts for all periods presented within the financial statements contained in the Quarterly Report on Form 10-Q, including the December 31, 2016 Balance Sheet amounts for Common Stock and additional paid-in capital, have been retroactively adjusted to reflect the Reverse Stock Split.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the accompanying notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. For a description of factors that may cause our actual results to differ materially from those anticipated in these forward-looking statements, please refer to the below section of this Quarterly Report on Form 10-Q titled “Cautionary Note Regarding Forward-Looking Statements.” Unless the context otherwise requires, all references to “we”, “us”, the “Company”, or “NeuroMetrix” in this Quarterly Report on Form 10-Q refer to NeuroMetrix, Inc.

Overview

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. Our business is fully integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. We derive revenues from the sale of medical devices and after-market consumable products and accessories. Our products are sold in the United States and selected overseas markets, and are cleared by the U.S. Food and Drug Administration, or FDA, and regulators in foreign jurisdictions where appropriate. We have two principal product lines:

• Wearable neuro-stimulation therapeutic devices

• Point-of-care neuropathy diagnostic tests

Our core expertise in biomedical engineering has been refined over nearly two decades of designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. We created the market for point-of-care nerve testing and were first to market with sophisticated, wearable technology for management of chronic pain. We also have an experienced management team and Board of Directors.

Chronic pain is a significant public health problem. It is defined by the National Institutes of Health as any pain lasting more than 12 weeks in contrast to acute pain, which is a normal bodily response to injury or trauma. Chronic pain conditions include painful diabetic neuropathy, or PDN, arthritis, fibromyalgia, sciatica, musculoskeletal pain, cancer pain and many others. Chronic pain may be triggered by an injury or there may be an ongoing cause such as disease or illness. There may also be no clear cause. Pain signals continue to be transmitted in the nervous system over extended periods of time often leading to other health problems. These can include fatigue, sleep disturbance, decreased appetite, and mood changes which cause difficulty in carrying out important activities and contributing to disability and despair. In general, chronic pain cannot be cured. Treatment of chronic pain is focused on reducing pain and improving function. The goal is effective pain management.

Chronic pain is widespread. It affects over 100 million adults in the United States and more than 1.5 billion people worldwide. The global market for pain management drugs and devices alone was valued at $35 billion in 2012. The estimated incremental impact of chronic pain on health care costs in the United States is over $250 billion per year and lost productivity is estimated to exceed $300 billion per year. Estimated out-of-pocket spending in the United States on chronic pain is $20 billion per year.

The most common approach to chronic pain is pain medication. This includes over-the-counter drugs (such as Advil and Motrin), and prescription drugs including anti-convulsants (such as Lyrica and Neurontin) and anti-depressants (such as Cymbalta and Elavil). Topical creams may also be used (such as Zostrix and Bengay). With severe pain, narcotic pain medications may be prescribed (such as codeine, fentanyl, morphine, and oxycodone). The approach to treatment is individualized, drug combinations may be employed, and the results are often hit or miss. Side effects and the potential for addiction are real and the risks are substantial.

Reflecting the difficulty in treating chronic pain, we believe that inadequate relief leads 25% to 50% of pain sufferers to turn to the over-the-counter market for supplements or alternatives to prescription pain medications. These include non-prescription medications, topical creams, lotions, electrical stimulators, dietary products, braces, sleeves, pads and other items. In total they account for over $4 billion in annual spending in the United States on pain relief products.

High frequency nerve stimulation is an established treatment for chronic pain supported by numerous clinical studies demonstrating efficacy. In simplified outline, the mechanism of action involves intensive nerve stimulation to activate the body’s central pain inhibition system resulting in widespread analgesia, or pain relief. The nerve stimulation activates brainstem

pain centers leading to the release of endogenous opioids that act primarily through the delta opioid receptor to reduce pain signal transmission through the central nervous system. This therapeutic approach is available through deep brain stimulation and through implantable spinal cord stimulation, both of which require surgery and have attendant risks. Non-invasive approaches to neuro-stimulation (transcutaneous electrical nerve stimulation, or TENS) have achieved limited efficacy in practice due to device limitations, ineffective dosing and low patient compliance.

Quell, our OTC wearable device for pain relief, was unveiled at the January 2015 Consumer Electronics Show (CES) and made commercially available in the United States during the second quarter of 2015. Quell revenues for fiscal years 2016 and 2015 were approximately $7.4 million and $2.1 million, respectively. Quell revenues for the nine months ended September 30, 2017 were approximately $8.7 million. Following commercial launch through September 30, 2017, approximately 113,968 Quell devices plus electrodes and accessories were shipped to consumers with a total invoiced value of $25.8 million, prior to the impact of product returns. Quell utilizes our patented 100% drug-free neuro-stimulation technology to provide relief from chronic intractable pain, such as nerve pain due to diabetes, fibromyalgia, arthritic pain, and lower back and leg pain. This advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the U.S. Food and Drug Administration (the "FDA") for treatment of chronic intractable pain without a doctor’s prescription. Users of the device have the option of using their smartphones to control pain therapy and to track sleep, activity, gait and therapy parameters. Quell is distributed in North America via e-commerce, including the Company’s website (www.quellrelief.com) and Amazon, via direct response television including QVC, via retail merchandisers including Target, CVS, Walgreens, Best Buy, Bed Bath and Beyond and via health care professionals such as pain management physician practices and podiatry practices. Distribution is supported by television promotion to expand product awareness. We believe there are significant opportunities to market Quell outside of the United States, particularly in Western Europe, Japan and China. We received regulatory approval to market Quell in the European Union and Australia and we anticipate initiating marketing in the future.

DPNCheck, our diagnostic test for peripheral neuropathies, was made commercially available in the fourth quarter of 2011. DPNCheck revenues for fiscal years 2016 and 2015 were approximately $2.5 million, and $2.3 million, respectively. DPNCheck revenues for the nine months ended September 30, 2017 were approximately $2.3 million. Our U.S. sales efforts focus on Medicare Advantage providers who assume financial responsibility and the associated risks for the health care costs of their patients. We believe that DPNCheck presents an attractive clinical case with early detection of neuropathy allowing for earlier clinical intervention to help mitigate the effects of neuropathy on both patient quality of life and cost of care. Also, the diagnosis and documentation of neuropathy provided by DPNCheck helps clarify the patient health profile which, in turn, may have a direct, positive effect on the Medicare Advantage premium received by the provider. We believe that attractive opportunities exist outside the United States, including Japan where we launched DPNCheck with our distribution partner Omron Healthcare in the third quarter of 2014; in China where we received regulatory approval and launched DPNCheck with our distribution partner Omron Healthcare in the fourth quarter of 2016; and in Mexico where our distributor Scienta Farma received regulatory approval and initiated sales in the fourth quarter of 2015.

Our products consist of a medical device used in conjunction with a consumable electrode or biosensor. Other accessories and consumables are also available to customers. Our goal for these products is to build an installed base of active customer accounts and distributors that regularly order aftermarket products to meet their needs. We successfully implemented this model when we started our business with the NC-stat system and applied it to subsequent product generations including ADVANCE. Our recent products, Quell and DPNCheck, conform to this model. Other products in our development pipeline are based on the device plus consumables business model.

Results of Operations

Comparison of Quarters Ended September 30, 2017 and 2016

Revenues

The following table summarizes our revenues:



	Quarters Ended September 30,
	2017		2016		Change		% Change
	(in thousands)
Revenues	$	3,546.7	$	3,389.4	$	157.3	4.6	%

Revenues include sales from Quell, DPNCheck and our legacy neurodiagnostic products. During the third quarter of 2017 total revenues increased by approximately $0.2 million, or 4.6%, from the third quarter of 2016.

Quell revenues were approximately $2.6 million and $2.1 million in the quarters ended September 30, 2017 and 2016, respectively. This increase of approximately $0.5 million was the largest contributor to overall revenue growth.

During the third quarter of 2017, 15,627 Quell devices and 28,702 electrode reorder packages with a total invoiced value of approximately $3.6 million were shipped to Quell customers. In the comparative third quarter of 2016, we shipped 12,086 Quell devices and 14,391 electrode reorder packages with a total invoiced value of approximately $2.9 million. Quell revenues are recorded at the point of shipment or, where distributors have a contractual right to return unsold merchandise, when Quell is sold through to the ultimate customer. In both cases, revenues are recorded net of a provision for product returns under our right-of-return policy.

In the third quarter of 2017 DPNCheck revenue of approximately $0.6 million reflected sales of 73 DPNCheck devices plus 39,950 biosensors. This compared with approximately $0.8 million in revenue in the third quarter of 2016 reflecting sales of 266 DPNCheck devices and 57,400 biosensors.

ADVANCE neurodiagnostic products contributed approximately $0.3 million in revenue for the third quarter of 2017, as compared to approximately $0.5 million in the third quarter of 2016.

Cost of Revenues and Gross Profit

The following table summarizes our cost of revenues and gross profit:



	Quarters Ended September 30,
	2017		2016		Change		% Change
	(in thousands)
Cost of revenues	$	2,041.0	$	2,031.8	$	9.2	0.5	%

Gross profit	$	1,505.7	$	1,357.6	$	148.1	10.9	%

Our cost of revenues remained flat at approximately $2.0 million in the third quarters of 2017 and 2016. Gross profit increased to 42.5% in the third quarter of 2017 from 40.1% in the third quarter of 2016. The expansion in gross profit reflects growing Quell sales, particularly higher margin electrodes, offset by increased sales weighting toward retail channels which carry tighter gross margins. As we build our installed base of Quell users, we expect accelerating growth in electrode sales at higher margins. Also, we expect continued growth in Quell sales to improve manufacturing cost absorption, contributing to future margin gains.

Operating Expenses

The following table summarizes our operating expenses:



	Quarters Ended September 30,
	2017		2016		Change			% Change
	(in thousands)
Operating expenses:
Research and development	$	840.6	$	1,202.7	$	(362.1	)	(30.1	)%
Sales and marketing	2,919.5		2,959.3		(39.8		)	(1.3	)%
General and administrative	1,258.5		1,165.8		92.7			8.0	%
Total operating expenses	$	5,018.6	$	5,327.8	$	(309.2	)	(5.8	)%

Research and Development

Research and development expenses for the quarters ended September 30, 2017 and 2016 were approximately $0.8 million and $1.2 million, respectively. The decrease of approximately $0.4 million relates primarily to a $0.4 million decrease in Quell development spending, a $0.1 million decrease in clinical study spending, partially offset by a $0.1 million increase in personnel spending.

Sales and Marketing

Sales and marketing expenses were approximately $2.9 million and $3.0 million for the quarters ended September 30, 2017 and September 30, 2016, respectively. The spending reflected an additional $0.1 million in television advertising, on-line advertising and paid search offset by a $0.1 million decrease in personnel spending.

General and Administrative

General and administrative expenses were approximately $1.3 million and $1.2 million for the quarters ended September 30, 2017 and September 30, 2016, respectively. The increase of approximately $0.1 million primarily reflected an additional $0.1 million in professional services expense.

Change in fair value of warrant liability

The change in fair value of warrant liability was approximately $327 and $56,248 for the quarters ended September 30, 2017 and September 30, 2016, respectively. The expense relates to the revaluation of the warrants' fair value utilizing a Black-Scholes model. The warrants were repurchased and retired in the Q3 2017 Offering, and as of September 30, 2017, no liability classified warrants remain outstanding.

Net loss per common share applicable to common stockholders, basic and diluted

The net loss per common share applicable to common stockholders, basic and diluted, was $3.11 and $6.11 for the quarters ended September 30, 2017 and 2016, respectively.

Net loss per common share applicable to common stockholders for the quarter ended September 30, 2017 of $3.11 reflected a deemed dividend attributable to preferred stockholders of $2.8 million, or $1.39 per share, related to our Q3 2017 Offering; and our net loss reported in our Statement of Operations for the quarter ended September 30, 2017 of $3.5 million, or $1.72 per share. The per share amount was calculated using 2,036,117 weighted average shares outstanding as of September 30, 2017.

Net loss per common share applicable to common stockholders for the quarter ended September 30, 2016 of $6.11 consisted of our net loss reported in our Statement of Operations for the quarter ended September 30, 2016 of $3.9 million, or $6.11. The per share amount was calculated using 639,512 weighted average shares outstanding as of September 30, 2016.

Comparison of Nine Months Ended September 30, 2017 and 2016

Revenues

The following table summarizes our revenues:



	Nine Months Ended September 30,
	2017		2016		Change		% Change
	(in thousands)
Revenues	$	12,162.9	$	8,312.1	$	3,850.8	46.3	%

Revenues include sales from Quell, DPNCheck and our legacy neurodiagnostic products. During the nine months ended September 30, 2017 total revenues increased by approximately $3.9 million, or 46.3%, from the nine months ended September 30, 2016.

Quell revenues were approximately $8.7 million and $4.9 million in the nine months ended September 30, 2017 and 2016, respectively. This increase of approximately $3.8 million was the largest contributor to overall revenue growth.

During the nine months ended September 30, 2017, 54,434 Quell devices and 84,846 electrode reorder packages with a total invoiced value of approximately $12.2 million were shipped to Quell customers. In the comparative nine months of 2016, we shipped 31,437 Quell devices and 32,666 electrode reorder packages with a total invoiced value of approximately $7.1 million. Quell revenues are recorded at the point of shipment or, where distributors have a contractual right to return unsold merchandise, when Quell is sold through to the ultimate customer. In both cases, revenues are recorded net of a provision for product returns under our right-of-return policy.

In the nine months ended September 30, 2017 DPNCheck revenue of approximately $2.3 million reflected sales of 362 DPNCheck devices plus 138,500 biosensors. This compared with approximately $1.7 million in revenue in the comparative nine months of 2016 reflecting sales of 447 DPNCheck devices and 125,300 biosensors.

ADVANCE neurodiagnostic products contributed approximately $1.2 million in revenue for the nine months ended September 30, 2017, as compared to approximately $1.6 million in the comparative nine months of 2016.

Cost of Revenues and Gross Profit

The following table summarizes our cost of revenues and gross profit:



	Nine Months Ended September 30,
	2017		2016		Change		% Change
	(in thousands)
Cost of revenues	$	7,378.0	$	5,086.7	$	2,291.3	45.0	%

Gross profit	$	4,784.9	$	3,225.4	$	1,559.5	48.4	%

Our cost of revenues increased to approximately $7.4 million in the nine months ended September 30, 2017 as compared to approximately $5.1 million in the nine months ended September 30, 2016. Gross profit increased to 39.3% in the nine months ended September 30, 2017 from 38.8% in the comparative nine months of 2016. The expansion in gross profit reflects growing Quell sales, particularly higher margin electrodes, offset by increased sales weighting toward retail channels which carry tighter gross margins. As we build our installed base of Quell users, we expect accelerating growth in electrode sales at higher margins. Also, we expect continued growth in Quell sales to improve manufacturing cost absorption, contributing to future margin gains.

Operating Expenses

The following table summarizes our operating expenses:



	Nine Months Ended September 30,
	2017		2016		Change			% Change
	(in thousands)
Operating expenses:
Research and development	$	2,621.4	$	3,487.3	$	(865.9	)	(24.8	)%
Sales and marketing	8,436.5		8,199.5		237.0			2.9	%
General and administrative	3,925.6		3,882.5		43.1			1.1	%
Total operating expenses	$	14,983.5	$	15,569.3	$	(585.8	)	(3.8	)%

Research and Development

Research and development expenses for the nine months ended September 30, 2017 and 2016 were approximately $2.6 million and $3.5 million, respectively. The decrease of approximately $0.9 million relates primarily to a $1.1 million decrease in Quell development spending partially offset by a $0.1 million increase in personnel spending.

Sales and Marketing

Sales and marketing expenses increased to approximately $8.4 million for the nine months ended September 30, 2017 from $8.2 million for the comparative nine months of 2016. The approximately $0.2 million increase in spending reflected an additional $0.7 million in television advertising, on-line advertising and paid search partially offset by sales and marketing headcount-related cost reductions of approximately $0.2 million from the comparative nine months of 2016 as compared to the nine months ended September 30, 2017.

General and Administrative

General and administrative expenses of approximately $3.9 million for the nine months ended September 30, 2017 were flat compared to the comparative nine months of 2016.

Change in fair value of warrant liability

The change in fair value of warrant liability was approximately $208,480 and $227,873 for the nine months ended September 30, 2017 and 2016, respectively. The expense relates to the revaluation of the warrants' fair value utilizing a Black-Scholes model. The warrants were repurchased and retired in the Q3 2017 Offering and, as of September 30, 2017, no liability classified warrants remain outstanding.

Net loss per common share applicable to common stockholders, basic and diluted

The net loss per common share applicable to common stockholders, basic and diluted, was $11.62 and $56.09 for the nine months ended September 30, 2017 and 2016, respectively.

Net loss per common share applicable to common stockholders for the nine months ended September 30, 2017 of $11.62 reflected a deemed dividend attributable to preferred stockholders of $6.9 million, or $4.74 per share, related to our Q1 2017 Offering and our Q3 2017 Offering; and our net loss reported in our Statement of Operations for the nine months ended September 30, 2017 of $10.0 million, or $6.88 per share. The per share amount was calculated using 1,450,237 weighted average shares outstanding as of September 30, 2017.

Net loss per common share applicable to common stockholders for the nine months ended September 30, 2016 of $56.09 reflected a deemed dividend attributable to preferred stockholders of $19.8 million, or $34.85 per share, related to our June 2016 Offering; and our net loss reported in our Statement of Operations for the nine months ended September 30, 2016 of $12.1 million, or $21.24 per share. The per share amount was calculated using 569,555 weighted average shares outstanding as of September 30, 2016.

Liquidity and Capital Resources

Our principal source of liquidity is our cash and cash equivalents, and to a lesser extent, product sales. As of September 30, 2017, cash and cash equivalents totaled $4.0 million. Our ability to generate revenue to fund our operations largely depends on the success of our wearable therapeutic products for chronic pain and our diagnostic products for neuropathy. A low level of market interest in Quell or DPNCheck, an accelerated decline in our neurodiagnostics consumables sales, or unanticipated increases in our operating or other costs would have an adverse effect on our liquidity and cash generated from operations. The following table sets forth information relating to our cash and cash equivalents:



	September 30, 2017		December 31, 2016		Change		% Change
	($ in thousands)

Cash and cash equivalents	$	3,969.2	$	3,949.1	$	20.1	0.5	%

In July 2017, we entered into agreements with respect to a $7.0 million private equity offering (the "Q3 2017 Offering") providing for the issuance of (i) 7,000 shares of Series F convertible preferred stock at a price of $1,000 per share, the repurchase and retirement of 4.2 million outstanding warrants at fair value for 3,621 Series F convertible preferred shares, and the adjustment of the conversion price for 21,053 Series D and E preferred shares to current market value. The Q3 2017 Offering will be completed in two tranches of $3.5 million each. The first tranche closed and was funded on July 12, 2017 and the second tranche is planned to close in October 2017. After fees and expenses, net proceeds of the Q3 2017 Offering were expected to be $6.6 million.

During the first quarter of 2017, we closed a securities purchase agreement relating to a $7 million private offering (the "Q1 2017 Offering") providing for the issuance of (i) 7,000 shares of Series E convertible preferred stock at a price of $1,000 per share, and (ii) warrants to purchase 1,250,000 shares of our Common Stock, at an exercise price of $5.60 per share. After fees and expenses, net proceeds of the Q1 2017 Offering were $6.3 million.

In order to supplement our access to capital, we are party to an amended Loan and Security Agreement, most recently amended on December 29, 2016, with a bank which provides us with a credit facility in the amount of $2.5 million on a revolving basis. The amended credit facility expires on January 15, 2018. Amounts borrowed under the credit facility will bear interest equal to the prime rate plus 0.5%. Any borrowings under the credit facility will be collateralized by our cash, accounts receivable, inventory, and equipment. The Credit Facility includes traditional lending and reporting covenants. These include certain financial covenants applicable to liquidity that are to be maintained by us. As of September 30, 2017, we were in compliance with these covenants and had not borrowed any funds under the credit facility. However, approximately $0.2 million of the amount under the Credit Facility is restricted to support letters of credit issued in favor of our facilities landlords. Consequently, the amount available for borrowing under the credit facility as of September 30, 2017 was approximately $2.3 million.

During the nine months ended September 30, 2017, cash and cash equivalents remained essentially flat reflecting $9.5 million of net cash usage for ongoing business operations partially offset by net proceeds of $3.3 million from the first tranche of the Q3 2017 Offering and $6.3 million from the Q1 2017 Offering.

In managing working capital, we focus on two important financial measurements as presented below:



	Quarters Ended September 30,		Year Ended December 31,
	2017	2016	2016

Days sales outstanding (days)	18	15	23
Inventory turnover rate (times per year)	5.0	7.4	6.1

Customer payment terms generally vary from payment-on-order for Quell e-commerce sales to 60 days from invoice date.

The following sets forth information relating to sources and uses of our cash:



	Nine Months Ended September 30,
	2017			2016
	(in thousands)
Net cash used in operating activities	$	(9,479.5	)	$	(11,457.1	)
Net cash used in investing activities	(70.2		)	(87.9		)
Net cash provided by financing activities	9,569.8			6,650.3

Our operating activities used $9.5 million for the nine months ended September 30, 2017, which was primarily attributable to our net loss of $10.0 million. This loss included non-cash credits of approximately $0.2 million for revaluing outstanding warrants at fair value. In addition, operating activities included increases in accrued expenses and compensation of $0.6 million and decreases in accounts receivable of $0.3 million, partially offset by increases in inventories of $0.5 million.

We held cash and cash equivalents of $4.0 million as of September 30, 2017. We believe that these resources, as well as $7.0 million in anticipated gross proceeds from the Q3 2017 Offering, including the first tranche of $3.5 million which closed on July 12, 2017, and a second tranche of $3.5 million which is expected to close in October 2017, and the cash to be generated from expected product sales will be sufficient to meet our projected operating requirements into the second quarter of 2018. We continue to face significant challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of our products; (b) changes we may make to the business that affect ongoing operating expenses; (c) changes we may make in our business strategy; (d) regulatory developments or inquiries affecting our existing products; (e) changes we may make in our research and development spending plans; and (f) other items affecting our forecasted level of expenditures and use of cash resources. Accordingly, we will need to raise additional funds to support our operating and capital needs in the second quarter of 2018 and beyond. These factors raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. We will attempt to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources. However, we may not be able to secure such financing in a timely manner or on favorable terms, if at all. We filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (the "SEC") covering shares of our common stock and other securities for sale, giving us the opportunity to raise funding when needed or otherwise considered appropriate at prices and on terms to be determined at the time of any such offerings. However, pursuant to applicable SEC rules, we only have the ability to sell shares under the shelf registration statement, during any 12-month period, in an amount less than or equal to one-third of the aggregate market value of our common stock held by non-affiliates. If we raise additional funds by issuing equity or debt securities, either through the sale of securities pursuant to a registration statement or by other means, our existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our potential products or proprietary technologies, or grant licenses on terms that are not favorable to us. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals would be adversely affected.

Off-Balance Sheet Arrangements, Contractual Obligation and Contingent Liabilities and Commitments

As of September 30, 2017, we did not have any off-balance sheet financing arrangements.

See Note 6, Commitments and Contingencies, of our Notes to Unaudited Financial Statements for information regarding commitments and contingencies.

Recent Accounting Pronouncements

evaluating the new standard and assessing the impact, if any, ASU 2016-2 will have on the Company’s financial statements and which adoption method will be used.

Cautionary Note Regarding Forward-Looking Statements

The statements contained in this Quarterly Report on Form 10-Q, including under the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other sections of this Quarterly Report, include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including, without limitation, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future, such as our estimates regarding anticipated operating losses, future revenues and projected expenses; our expectations for commercialization of our Quell product outside the United States; our future liquidity and our expectations regarding our needs for and ability to raise additional capital; our ability to manage our expenses effectively and raise the funds needed to continue our business; our belief that there are unmet needs for the management of chronic pain and in the diagnosis and treatment of diabetic neuropathy; our expectations surrounding Quell and DPNCheck; our expected timing and our plans to develop and commercialize our products; our ability to meet our proposed timelines for the commercial availability of our products; our ability to obtain and maintain regulatory approval of our existing products and any future products we may develop; regulatory and legislative developments in the United States and foreign countries; the performance of our third-party manufacturers; our ability to obtain and maintain intellectual property protection for our products; the successful development of our sales and marketing capabilities; the size and growth of the potential markets for our products and our ability to serve those markets; our plan to make Quell more broadly available through retail distribution; our belief that there are significant opportunities to market Quell outside the United States; our estimate of our customer returns of our products; the rate and degree of market acceptance of any future products; our reliance on key scientific management or personnel; the payment and reimbursement methods used by private or government third party payers; and other factors discussed elsewhere in this Quarterly Report on Form 10-Q. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this quarterly report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section titled “Risk Factors” below and in our Annual Report on Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We do not use derivative financial instruments in our investment portfolio and have no foreign exchange contracts. Our financial instruments consist of cash and cash equivalents. We consider investments that, when purchased, have a remaining maturity of 90 days or less to be cash equivalents. The primary objectives of our investment strategy are to preserve principal, maintain proper liquidity to meet operating needs, and maximize yields. To minimize our exposure to an adverse shift in interest rates, we invest mainly in cash equivalents and short-term investments with a maturity of twelve months or less and maintain an average maturity of twelve months or less. We do not believe that a notional or hypothetical 10% change in interest rate percentages would have a material impact on the fair value of our investment portfolio or our interest income.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2017, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during the quarter ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

While we are not currently a party to any material legal proceedings, we could become subject to legal proceedings in the ordinary course of business. We do not expect any such potential items to have a significant impact on our financial position.

Item 1A. Risk Factors

There have been no material changes in the risk factors described in “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

The Company has received a Civil Investigative Demand (“CID”) from the United States Federal Trade Commission (“FTC”). The CID requests information in connection with an FTC review for compliance of the Company’s representations about Quell with Sections 5 and 12 of the FTC Act. The Company is in the process of producing documents and information in response to the CID. To the knowledge of the Company, no complaint has been filed against the Company; however, no assurance can be given as to the timing or outcome of the investigation.

The Company intends to repurchase, from time to time, warrants to purchase its common stock that are traded on Nasdaq under the symbol NUROW. The Company may expend up to $25,000 in making these purchases on Nasdaq from time to time.

Item 6. Exhibits

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this quarterly report, which Exhibit Index is incorporated herein by this reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		NEUROMETRIX, INC.

October 20, 2017	/s/	SHAI N. GOZANI, M.D., PH. D.
		Shai N. Gozani, M.D., Ph. D.
		Chairman, President and Chief Executive Officer

October 20, 2017	/s/	THOMAS T. HIGGINS
		Thomas T. Higgins
		Senior Vice President, Chief Financial Officer and Treasurer

EXHIBIT INDEX



Exhibit No.		Description

31.1		Certification of Principal Executive Officer Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. Filed herewith.

31.2		Certification of Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith.

32		Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350. Furnished herewith.

101		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Balance Sheets at September 30, 2017 and December 31, 2016, (ii) Statements of Operations for the quarters and nine months ended September 30, 2017 and 2016, (iii) Statements of Cash Flows for the nine months ended September 30, 2017 and 2016, and (iv) Notes to Financial Statements.

EX-31.1 2 a10q9302017exhibit311.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

CERTIFICATION

I, Shai N. Gozani, M.D., Ph.D., certify that:



1.	I have reviewed this Quarterly Report on Form 10-Q of NeuroMetrix, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Date:	October 20, 2017	/s/ SHAI N. GOZANI, M.D., PH.D.
		Shai N. Gozani, M.D., Ph.D.
		Chairman, President and Chief Executive Officer

EX-31.2 3 a10q9302017exhibit312.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

CERTIFICATION



I, Thomas T. Higgins, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of NeuroMetrix, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Date:	October 20, 2017	/s/ THOMAS T. HIGGINS
		Thomas T. Higgins
		Senior Vice President, Chief Financial Officer and Treasurer

EX-32 4 a10q9302017exhibit32.htm EXHIBIT 32 Exhibit

EXHIBIT 32

CERTIFICATION

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of NeuroMetrix, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report for the quarter ended September 30, 2017 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.



	/s/ SHAI N. GOZANI, M.D., PH.D.
	Shai N. Gozani, M.D., Ph.D.
	Chairman, President and Chief Executive Officer


	/s/ THOMAS T. HIGGINS
	Thomas T. Higgins
	Senior Vice President, Chief Financial Officer and Treasurer

October 20, 2017

This certification is being furnished and not filed, and shall not be incorporated into any document for any purpose, under the Securities Exchange Act of 1934 or the Securities Act of 1933.

EX-101.INS 5 nuro-20170930.xml XBRL INSTANCE DOCUMENT 0001289850 2017-01-01 2017-09-30 0001289850 2017-10-13 0001289850 2016-12-31 0001289850 2017-09-30 0001289850 nuro:NonConvertiblePreferredStockMember 2016-12-31 0001289850 us-gaap:ConvertiblePreferredStockMember 2017-09-30 0001289850 us-gaap:ConvertiblePreferredStockMember 2016-12-31 0001289850 nuro:NonConvertiblePreferredStockMember 2017-09-30 0001289850 2017-07-01 2017-09-30 0001289850 2016-07-01 2016-09-30 0001289850 2016-01-01 2016-09-30 0001289850 2016-09-30 0001289850 2015-12-31 0001289850 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember nuro:SecondCustomerMember 2016-01-01 2016-09-30 0001289850 us-gaap:MinimumMember 2017-01-01 2017-09-30 0001289850 2016-01-01 2016-12-31 0001289850 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember nuro:OneCustomerMember 2017-07-01 2017-09-30 0001289850 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember nuro:OneCustomerMember 2017-01-01 2017-09-30 0001289850 us-gaap:ScenarioForecastMember nuro:Q32017OfferingTrancheTwoMember 2017-10-01 2017-10-31 0001289850 nuro:A2017OfferingsMember 2017-01-01 2017-09-30 0001289850 us-gaap:MaximumMember 2017-01-01 2017-09-30 0001289850 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nuro:TwoCustomersMember 2017-01-01 2017-09-30 0001289850 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nuro:TwoCustomersMember 2016-01-01 2016-12-31 0001289850 2017-05-12 2017-05-12 0001289850 us-gaap:ConvertiblePreferredStockMember 2017-01-01 2017-09-30 0001289850 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001289850 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001289850 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001289850 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001289850 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001289850 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001289850 us-gaap:ConvertiblePreferredStockMember 2017-07-01 2017-09-30 0001289850 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001289850 us-gaap:ConvertiblePreferredStockMember 2016-07-01 2016-09-30 0001289850 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001289850 us-gaap:ConvertiblePreferredStockMember 2016-01-01 2016-09-30 0001289850 nuro:SevenYearOperatingLeaseAgreementMember 2015-02-20 2015-02-20 0001289850 nuro:FiveYearOperatingLeaseAgreementMember 2014-08-01 2014-08-31 0001289850 nuro:SevenYearOperatingLeaseAgreementMember 2014-09-01 2014-09-30 0001289850 nuro:FiveYearOperatingLeaseAgreementMember 2014-12-15 2014-12-15 0001289850 nuro:SevenYearOperatingLeaseAgreementMember 2017-09-30 0001289850 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001289850 us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001289850 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001289850 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0001289850 nuro:TwoThousandFourteenOfferingWarrantsMember us-gaap:WarrantMember 2017-09-30 0001289850 nuro:TwoThousandFourteenOfferingWarrantsMember us-gaap:WarrantMember 2017-01-01 2017-09-30 0001289850 nuro:TwoThousandThirteenOfferingWarrantsMember 2017-01-01 2017-09-30 0001289850 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001289850 nuro:TwoThousandThirteenOfferingWarrantsMember us-gaap:WarrantMember 2016-12-31 0001289850 nuro:TwoThousandThirteenOfferingWarrantsMember us-gaap:WarrantMember 2017-01-01 2017-09-30 0001289850 us-gaap:WarrantMember 2016-12-31 0001289850 nuro:TwoThousandFourteenOfferingWarrantsMember 2017-01-01 2017-09-30 0001289850 us-gaap:WarrantMember 2017-09-30 0001289850 nuro:TwoThousandThirteenOfferingWarrantsMember us-gaap:WarrantMember 2017-09-30 0001289850 nuro:TwoThousandFourteenOfferingWarrantsMember us-gaap:WarrantMember 2016-12-31 0001289850 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001289850 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001289850 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001289850 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001289850 nuro:TwoThousandFourteenOfferingWarrantsMember 2016-01-01 2016-12-31 0001289850 nuro:TwoThousandThirteenOfferingWarrantsMember 2016-12-31 0001289850 nuro:TwoThousandThirteenOfferingWarrantsMember 2016-01-01 2016-12-31 0001289850 nuro:TwoThousandFourteenOfferingWarrantsMember 2016-12-31 0001289850 us-gaap:PrimeRateMember 2017-01-01 2017-09-30 0001289850 nuro:SeriesFConvertiblePreferredStockMember 2017-09-30 0001289850 nuro:SeriesDConvertiblePreferredStockMember 2016-12-31 0001289850 nuro:SeriesEConvertiblePreferredStockMember 2016-12-31 0001289850 nuro:SeriesEConvertiblePreferredStockMember 2017-09-30 0001289850 nuro:SeriesBConvertiblePreferredStockMember 2017-09-30 0001289850 nuro:SeriesDConvertiblePreferredStockMember 2017-09-30 0001289850 nuro:SeriesFConvertiblePreferredStockMember 2016-12-31 0001289850 nuro:SeriesBConvertiblePreferredStockMember 2016-12-31 0001289850 nuro:TwoThousandAndSeventeenOfferingMember 2017-01-01 2017-03-31 0001289850 us-gaap:WarrantMember nuro:Q12017OfferingMember 2017-03-31 0001289850 us-gaap:SeriesFPreferredStockMember 2017-09-30 0001289850 us-gaap:CommonStockMember nuro:June2016OfferingMember 2016-06-30 0001289850 nuro:Q32017OfferingTrancheOneMember 2017-07-01 2017-09-30 0001289850 us-gaap:SeriesDPreferredStockMember 2017-01-01 2017-09-30 0001289850 us-gaap:CommonStockMember nuro:TwoThousandAndSeventeenOfferingMember 2017-03-31 0001289850 us-gaap:SeriesFPreferredStockMember 2017-01-01 2017-09-30 0001289850 us-gaap:SeriesFPreferredStockMember nuro:Q32017OfferingTrancheOneMember 2017-07-01 2017-09-30 0001289850 us-gaap:WarrantMember nuro:Q12017OfferingMember 2017-01-01 2017-03-31 0001289850 us-gaap:SeriesFPreferredStockMember nuro:Q32017OfferingTrancheTwoMember 2017-07-01 2017-09-30 0001289850 nuro:June2016OfferingMember 2016-06-01 2016-06-30 0001289850 nuro:SeriesEConvertiblePreferredStockMember nuro:Q12017OfferingMember 2017-03-31 0001289850 us-gaap:PreferredStockMember nuro:A2017OfferingsMember 2017-01-01 2017-09-30 0001289850 nuro:SeriesDConvertiblePreferredStockMember nuro:TwoThousandAndSeventeenOfferingMember 2017-03-31 0001289850 nuro:SeriesEConvertiblePreferredStockMember nuro:Q32017OfferingMember 2017-09-30 0001289850 us-gaap:PreferredStockMember nuro:Q32017OfferingMember 2017-07-01 2017-09-30 0001289850 us-gaap:PreferredStockMember nuro:A2017OfferingsMember 2017-09-30 0001289850 us-gaap:PreferredStockMember nuro:Q12017OfferingMember 2017-01-01 2017-03-31 0001289850 nuro:SeriesDConvertiblePreferredStockMember nuro:Q32017OfferingMember 2017-09-30 0001289850 us-gaap:SeriesCPreferredStockMember nuro:June2016OfferingMember 2016-06-01 2016-06-30 0001289850 us-gaap:SeriesFPreferredStockMember nuro:Q32017OfferingTrancheOneMember 2017-09-30 0001289850 nuro:SeriesEConvertiblePreferredStockMember nuro:TwoThousandAndSeventeenOfferingMember 2017-01-01 2017-03-31 0001289850 us-gaap:SeriesDPreferredStockMember 2017-09-30 0001289850 us-gaap:WarrantMember nuro:TwoThousandAndSeventeenOfferingMember 2017-03-31 0001289850 us-gaap:PreferredStockMember nuro:Q32017OfferingMember 2017-01-01 2017-09-30 0001289850 us-gaap:SeriesFPreferredStockMember nuro:Q32017OfferingTrancheTwoMember 2017-09-30 0001289850 us-gaap:CommonStockMember 2017-09-30 0001289850 us-gaap:SeriesDPreferredStockMember nuro:June2016OfferingMember 2016-06-01 2016-06-30 0001289850 us-gaap:SeriesDPreferredStockMember nuro:June2016OfferingMember 2016-06-30 0001289850 2017-05-12 0001289850 2017-05-11 xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares nuro:extension_option false --12-31 Q3 2017 2017-09-30 10-Q 0001289850 2345519 Smaller Reporting Company NeuroMetrix, Inc. NURO 488200 454730 P5Y 2934484 4641 0 4641 0 0 4641 4641 2.63 2.63 0 -40772 0 244611 -177999 -66612 -244611 7500000 7000000 1 1 147000 21300 0 0 147000 21300 7000 10621 P60D P30D 226731 318761 0 450000 450000

734048

725224

738729

423444

28100

335600

1648731

1911062

390800

343000

183439463

192975377

25000

4971423

3525872

58663

1386888

3643286

2621450

37709

984127

7728775

1206504

100237

6422034

7896343

3469612

98642

4328089

8283891

8772656

7586923

8220671

833831

197370

12462872

7568186

3949135

3969218

4000000

833831

197370

-4894686

20083

13.52

5.60

5.6

1475069

1250000

3621

0.0001

100000000

836862

2145519

836862

2145519

10147721

1268440

215

0.11

0.41

0.21

0.28

0.18

3149.72

-1301.85

495000

809103

2031823

5086706

2040997

7378001

0.005

910595

1466230

1247545

2272736

628236

925794

189224

198892

19800000

4000000

2800000

-6.11

-56.09

-3.11

-11.62

307471

692937

418881

P2Y7M6D

-56248

-227873

-327

-208480

65.28

64.00

4.96

P2Y6M

P1Y5M

P5Y

0.6419

0.7161

0.702

0.0133

0.0099

0.0204

147278

61202

208480

40772

34833

5939

4112

529

4641

1165815

3882461

1258466

3925595

1357604

3225390

1505683

4784860

-287427

-22074

-236447

-315285

634181

647797

402178

297558

73072

533836

408532

365547

5772

17030

3554

11018

630361

780589

1252238

1786074

466906

914150

154971

91335

275961

P5Y

P7Y

3323127

4255017

8283891

8772656

3318486

4255017

4641

2018-01-15

2500000

2300000

6650316

9569800

-87884

-70226

-11457118

-9479491

-3908153

-12098928

-3508983

-9979179

-3908153

-31945305

-6342081

-16853959

5327777

15569221

5018547

14983537

-3970173

-12343831

-3512864

-10198677

7598

37792

245752

215724

619309

1346942

87884

70226

19846377

2833098

6874780

0.001

5000000

500

17202.65

500

14052.93

7000

5819.15

500

17202.65

19458.90

500

14052.93

7000

5819.15

14052.93

1646821

2041935

164262

134695

6700000

6300000

3300000

12900000

6650316

9569800

45879

112008

532706

417290

488200

454730

1202651

3487291

840577

2621445

-178478801

-188457980

-188500000

3389427

8312096

3546680

12162861

3500000

3622219

3500000

14000000

2959311

8199469

2919504

8436497

176684

170093

5.92

1000

7000

3500

21300

13800

4184483

4960764

4517639

0.125

3490000

639512

569555

2036117

1450237

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Fair Value Measurements and Disclosures Topic of the Codification defines fair value, establishes a framework for measuring fair value in applying generally accepted accounting principles, and expands disclosures about fair value measurements. This Codification topic identifies two kinds of inputs that are used to determine the fair value of assets and liabilities: observable and unobservable. Observable inputs are based on market data or independent sources while unobservable inputs are based on the Company’s own market assumptions. Once inputs have been characterized, this Codification topic requires companies to prioritize the inputs used to measure fair value into one of three broad levels. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values identified by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values identified by Level 3 inputs are unobservable data points and are used to measure fair value to the extent that observable inputs are not available. Unobservable inputs reflect the Company’s own assumptions about the assumptions that market participants would use at pricing the asset or liability.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at September 30, 2017 Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted Prices in<br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant<br clear="none"/>Unobservable<br clear="none"/>Inputs<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities, which relate to warrants issued by the Company in offerings in 2013 and 2014, between </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liability from repricing (see Note 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,999</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(208,480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchase and retirement of warrants (see Note 9)</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at December 31, 2016 Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted Prices in<br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant<br clear="none"/>Unobservable<br clear="none"/>Inputs<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the lack of market quotes relating to our common stock warrants then outstanding, the fair value of the common stock warrants was determined at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> using the Black-Scholes model, which is based on Level 3 inputs. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, inputs used in the Black-Scholes model are presented below. The assumptions used may change as the underlying sources of these assumptions and market conditions change. Based on the Black-Scholes model, the Company recorded a common stock warrants liability of </font><font style="font-family:inherit;font-size:10pt;">$4,641</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Black-Scholes Inputs to Warrant Liability Valuation at December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Risk-Free Interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dividends</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2014 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">65.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">64.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2 years, 6 months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">none</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2013 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">64.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">71.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1 year, 5 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">none</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities, which relate to warrants issued by the Company in offerings in 2013 and 2014, between </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013 Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liability from repricing (see Note 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,999</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(208,480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchase and retirement of warrants (see Note 9)</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2016-2, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;"> (“ASU 2016-2”). ASU 2016-2 requires that lessees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. The provisions of this guidance are effective for annual periods beginning after December 31, 2018, and for interim periods therein. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2016-2 will have on the Company’s financial statements and which adoption method will be used.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB and the International Accounting Standards Board (“IASB”) jointly issued Accounting Standards Update (“ASU”) No. 2014-9, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (“ASU 2014-9”), a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance. The objective of ASU 2014-9 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</font><font style="font-family:inherit;font-size:10pt;"> which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. An entity can elect to adopt ASU 2014-9 using one of two methods, either full retrospective adoption to each prior reporting period, or recognizing the cumulative effect of adoption at the date of initial application. In March 2016, the FASB issued ASU No. 2016-8, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)</font><font style="font-family:inherit;font-size:10pt;">, which clarifies the implementation guidance on principal versus agent considerations. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2014-9 will have on the Company’s financial statements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales return allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">488,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising and promotion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warranty reserve</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,911,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,648,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in calculating net loss per share amounts, shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarters Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,206,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,525,872</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,469,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,621,450</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,422,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,386,888</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,328,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">984,127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,728,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,971,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,896,343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,643,286</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at December 31, 2016 Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted Prices in<br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant<br clear="none"/>Unobservable<br clear="none"/>Inputs<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,831</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements at September 30, 2017 Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted Prices in<br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant<br clear="none"/>Unobservable<br clear="none"/>Inputs<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of the following: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchased components</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in progress</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">780,589</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630,361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,786,074</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,252,238</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock and convertible preferred stock consist of the following:</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2017 and December 31, 2016; no shares issued and outstanding at September 30, 2017 and December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B convertible preferred stock, $0.001 par value, 147,000 shares designated at September 30, 2017 and December 31, 2016, and 500 shares issued and outstanding at September 30, 2017 and December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series D convertible preferred stock, $0.001 par value, 21,300 shares designated at September 30, 2017 and December 31, 2016, 14,052.93 and 17,202.65 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series E convertible preferred stock, $0.001 par value, 7,000 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 7,000 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series F convertible preferred stock, $0.001 par value, 10,621 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 5,819.15 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 6 nuro-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2107100 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Business and Basis of Presentation (Detail) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Business and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Commitments and Contingencies (Detail) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Comprehensive Loss (Detail) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Credit Facility link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Credit Facility (Detail) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Fair Value Measurements - Black-Scholes Inputs to Warrant Liability Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Liabilities (Detail) (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Reverse Stock Split link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Reverse Stock Split (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Stockholders' Equity - Preferred Stock and Convertible Preferred Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nuro-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 nuro-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 nuro-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity [Abstract] Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Payables and Accruals [Abstract] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Option Indexed to Issuers Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Options Employee Stock Option [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Warrants Warrant [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Convertible preferred stock Convertible Preferred Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total antidilutive securities excluded from the computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Debt Disclosure [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Prime Rate Prime Rate [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Revolving credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Credit facility expiration date Line of Credit Facility, Expiration Date Interest rate over prime rate Debt Instrument, Basis Spread on Variable Rate Credit facility limit restricted to support letter of credit Restricted Cash Collateral Letters Of Credit Restricted Cash Collateral Letters of Credit Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Accounting Policies [Abstract] Our Business-An Overview Business Description And Basis Of Presentation [Policy Text Block] Business description and basis of presentation policy text block. Unaudited Interim Financial Statements Interim Disclosure [Policy Text Block] Interim disclosure policy text block. Revenues Revenue Recognition, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Inventory Disclosure [Abstract] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] 2014 Offering Two Thousand Fourteen Offering Warrants [Member] 2013 Offering Two Thousand Thirteen Offering Warrants [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Change in fair value of warrant liability from repricing Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) From Repricing Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) From Repricing Included in Earnings Change in fair value of warrant liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Repurchase and retirement of warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Ending Balance Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Changes in Fair Value of Company's Level 3 Financial Liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Black-Scholes Inputs to Warrant Liability Valuation Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Non-Convertible Preferred Stock Non-Convertible Preferred Stock [Member] Non-Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Fixed assets, net Property, Plant and Equipment, Net Other long-term assets Prepaid Expense and Other Assets, Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Total current liabilities Liabilities, Current Common stock warrants Common Stock Warrants Common stock warrants. Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock Preferred Stock, Value, Issued Common stock, $0.0001 par value; 100,000,000 shares authorized at September 30, 2017 and December 31, 2016; 2,145,519 and 836,862 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total assets measured at fair value on recurring basis Assets, Fair Value Disclosure, Recurring Liabilities [Abstract] Liabilities [Abstract] Common stock warrants Common Stock warrants Fair Value Disclosure Common stock warrants fair value disclosure Total liabilities measured at fair value on recurring basis Liabilities, Fair Value Disclosure, Recurring Commitments and Contingencies Disclosure [Abstract] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Period [Axis] Period [Axis] Period [Axis] Period [Domain] Period [Domain] Period [Domain] 5-year operating lease agreement Five Year Operating Lease Agreement [Member] 7-year operating lease agreement Seven Year Operating Lease Agreement [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Operating lease, term of contract Lessee Leasing Arrangements, Operating Leases, Term of Contract Operating lease, number of extension options Lessee Leasing Arrangements, Operating Leases, Number of Extension Options Lessee Leasing Arrangements, Operating Leases, Number of Extension Options Operating lease, renewal term Lessee Leasing Arrangements, Operating Leases, Renewal Term Monthly base rent Operating Leases, Rent Expense, Minimum Rentals Excess cost of leasehold improvements Leasehold Improvements, Gross Preferred stock and convertible preferred stock Schedule of Stock by Class [Table Text Block] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Accrued Expenses Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Inventories Inventory Disclosure [Text Block] Purchased components Inventory, Raw Materials, Net of Reserves Work in progress Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Inventories Common stock warrants liability Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Stock-based compensation Share-based Compensation Change in fair value of warrant liability Fair Value Adjustment of Warrants Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current and long-term assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and compensation Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of fixed assets Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net proceeds from issuance of stock and warrants Proceeds from (Repurchase of) Equity Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net increase/(decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Change in fair value of warrant liability from repricing Fair Value Adjustment of Warrants, Repricing Fair Value Adjustment of Warrants, Repricing Exchange of warrant liability for Series F Preferred Stock Exchange Of Warrant Liability For Preferred Stock Exchange Of Warrant Liability For Preferred Stock Common stock issued to settle employee incentive compensation obligation Stock Issuance Settle Incentive Compensation Obligation Stock issuance to settle incentive compensation obligation Reverse Stock Split Stockholders' Equity Note Disclosure [Text Block] Credit Facility Debt Disclosure [Text Block] Organization and Basis Of Presentation [Table] Organization and Basis Of Presentation [Table] Organization And Basis Of Presentation [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] 2017 Offerings 2017 Offerings [Member] 2017 Offerings [Member] Q3 2017 Offering Tranche Two Q3 2017 Offering Tranche Two [Member] Q3 2017 Offering Tranche Two [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] One Customer One Customer [Member] One Customer One Different Customer Second Customer [Member] Second Customer [Member] Two Customers Two Customers [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue Sales Revenue, Net [Member] Accounts Receivable Accounts Receivable [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Organization And Basis Of Presentation [Line Items] Organization and Basis Of Presentation [Line Items] Organization And Basis Of Presentation [Line Items] Gross proceeds from issuance of equity Sale of Stock, Consideration Received on Transaction Net proceeds from issuance of stock and warrants Proceeds from Issuance or Sale of Equity Accumulated deficit Value of shipments made but not yet sold Deferred Revenue and Credits, Current Reduction to accounts receivable Other Deferred Credits, Current Deferred costs of goods sold Deferred Costs, Current Product sales right of return term Product Sales Right of Return Term The term represents product sales right of return. Provision for expected returns recorded as accrued expense Provision for Doubtful Accounts Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current EX-101.PRE 10 nuro-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Oct. 13, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	NeuroMetrix, Inc.
Entity Central Index Key	0001289850
Trading Symbol	NURO
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,345,519

XML 12 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,969,218	$ 3,949,135
Accounts receivable, net	423,444	738,729
Inventories	1,786,074	1,252,238
Prepaid expenses and other current assets	2,041,935	1,646,821
Total current assets	8,220,671	7,586,923
Fixed assets, net	417,290	532,706
Other long-term assets	134,695	164,262
Total assets	8,772,656	8,283,891
Current liabilities:
Accounts payable	725,224	734,048
Accrued compensation	692,937	307,471
Accrued expenses	1,911,062	1,648,731
Deferred revenue	925,794	628,236
Total current liabilities	4,255,017	3,318,486
Common stock warrants	0	4,641
Total liabilities	4,255,017	3,323,127
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized at September 30, 2017 and December 31, 2016; 2,145,519 and 836,862 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	215	84
Additional paid-in capital	192,975,377	183,439,463
Accumulated deficit	(188,457,980)	(178,478,801)
Total stockholders’ equity	4,517,639	4,960,764
Total liabilities and stockholders’ equity	8,772,656	8,283,891
Non-Convertible Preferred Stock
Stockholders’ equity:
Preferred stock	0	0
Convertible preferred stock
Stockholders’ equity:
Preferred stock	$ 27	$ 18

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	2,145,519	836,862
Common stock, shares outstanding (in shares)	2,145,519	836,862

XML 14 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenues	$ 3,546,680	$ 3,389,427	$ 12,162,861	$ 8,312,096
Cost of revenues	2,040,997	2,031,823	7,378,001	5,086,706
Gross profit	1,505,683	1,357,604	4,784,860	3,225,390
Operating expenses:
Research and development	840,577	1,202,651	2,621,445	3,487,291
Sales and marketing	2,919,504	2,959,311	8,436,497	8,199,469
General and administrative	1,258,466	1,165,815	3,925,595	3,882,461
Total operating expenses	5,018,547	5,327,777	14,983,537	15,569,221
Loss from operations	(3,512,864)	(3,970,173)	(10,198,677)	(12,343,831)
Interest income	3,554	5,772	11,018	17,030
Change in fair value of warrant liability	327	56,248	208,480	227,873
Net loss	(3,508,983)	(3,908,153)	(9,979,179)	(12,098,928)
Net loss applicable to common stockholders:
Deemed dividends attributable to preferred shareholders	(2,833,098)	0	(6,874,780)	(19,846,377)
Net loss applicable to common stockholders	$ (6,342,081)	$ (3,908,153)	$ (16,853,959)	$ (31,945,305)
Net loss per common share applicable to common stockholders, basic and diluted (in dollars per share)	$ (3.11)	$ (6.11)	$ (11.62)	$ (56.09)
Weighted average number of common shares outstanding, basic and diluted (in shares)	2,036,117	639,512	1,450,237	569,555

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (9,979,179)	$ (12,098,928)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	198,892	189,224
Stock-based compensation	170,093	176,684
Change in fair value of warrant liability	(208,480)	(227,873)
Changes in operating assets and liabilities:
Accounts receivable	315,285	236,447
Inventories	(533,836)	(73,072)
Prepaid expenses and other current and long-term assets	(365,547)	(408,532)
Accounts payable	(22,074)	(287,427)
Accrued expenses and compensation	647,797	634,181
Deferred revenue	297,558	402,178
Net cash used in operating activities	(9,479,491)	(11,457,118)
Cash flows from investing activities:
Purchases of fixed assets	(70,226)	(87,884)
Net cash used in investing activities	(70,226)	(87,884)
Cash flows from financing activities:
Net proceeds from issuance of stock and warrants	9,569,800	6,650,316
Net cash provided by financing activities	9,569,800	6,650,316
Net increase/(decrease) in cash and cash equivalents	20,083	(4,894,686)
Cash and cash equivalents, beginning of period	3,949,135	12,462,872
Cash and cash equivalents, end of period	3,969,218	7,568,186
Supplemental disclosure of cash flow information:
Change in fair value of warrant liability from repricing	244,611	0
Exchange of warrant liability for Series F Preferred Stock	(40,772)	0
Common stock issued to settle employee incentive compensation obligation	$ 0	$ 318,761

XML 16 R6.htm IDEA: XBRL DOCUMENT

Business and Basis of Presentation	9 Months Ended
Business and Basis of Presentation	Sep. 30, 2017
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc. or the Company, is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The Company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The Company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The Company maintains an active research effort and has several pipeline programs. The Company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. During the first nine months of 2017, the Company completed two equity offerings, detailed in Note 9 to the financial statements, with anticipated gross proceeds of $14.0 million and anticipated net proceeds of approximately $12.9 million after deducting fees and expenses. Gross proceeds of $3.5 million from the second tranche of the Q3 2017 Offering are expected to be received by the Company in October of 2017. The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses from operations and negative cash flows from operating activities. At September 30, 2017, the Company had an accumulated deficit of $188.5 million. The Company held cash and cash equivalents of $4.0 million as of September 30, 2017. The Company believes that these resources, cash proceeds from the second 2017 equity offering, and the cash to be generated from expected product sales will be sufficient to meet its projected operating requirements into the second quarter of 2018. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products and the uncertainty of future revenues; (b) changes the Company may make to the business that affect ongoing operating expenses; (c) changes the Company may make in its business strategy; (d) regulatory developments or inquiries affecting the Company’s existing products and products under development; (e) changes the Company may make in its research and development spending plans; and (f) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company will need to raise additional funds to support its operating and capital needs in the second quarter of 2018 and beyond. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company intends to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected. Certain prior period amounts have been adjusted to reflect the Company's 1-for-8 reverse stock split effected May 11, 2017. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of September 30, 2017, unaudited statements of operations for the quarters and nine months ended September 30, 2017 and 2016 and the unaudited statements of cash flows for the nine months ended September 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2016 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair statement of the Company’s financial position and operating results. Operating results for the quarters and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on February 9, 2017 (File No. 001-33351), or the Company’s 2016 Form 10-K. Revenues The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured. Revenues associated with the Company’s medical devices and consumables are generally recognized upon shipment, assuming all other revenue recognition criteria have been met. Revenue associated with shipments made to distributors who have the right to return any unsold product is recognized once the product is sold by the distributor to the end customer (i.e. under a sell-through model), assuming all other revenue recognition criteria have been met. Cash received prior to all the conditions for revenue recognition being met is recorded as deferred revenue. Deferred revenue recorded prior to cash receipt is recorded as an offset to accounts receivable. As of September 30, 2017 the total value of shipments made to sell-through distributors but not yet sold through to end customers totaled $2,272,736. Of this total, $1,346,942 was recorded as a reduction to accounts receivable and $925,794 was recorded in deferred revenue, as cash had been received. As of December 31, 2016, the total value of shipments that had been made to sell-through distributors but had not yet been sold through to end customers totaled $1,247,545. Of this total, $619,309 was recorded as a reduction to accounts receivable and $628,236 was recorded in deferred revenue, as cash had been received. Related costs of goods sold of $1,466,230 and $910,595 have been deferred and recorded in prepaid expenses and other current assets as of September 30, 2017 and December 31, 2016, respectively. Revenue recognition involves judgments, including assessments of expected returns from customers who have the right to return product for any reason under 30 days or 60 days rights of return. Where the Company can reasonably estimate future returns, it recognizes revenues and records as a reduction of revenue a provision for estimated returns. The Company analyzes various factors, including its historical product returns in arriving at this judgment. Changes in judgments or estimates could materially impact the timing and amount of revenues and costs recognized. The provision for expected returns recorded in accrued expense was $454,730 and $488,200 as of September 30, 2017 and December 31, 2016, respectively. Accounts receivable are recorded net of the allowance for doubtful accounts which represents the Company’s best estimate of probable credit losses. Allowance for doubtful accounts was $25,000 as of September 30, 2017 and December 31, 2016. One customer accounted for 21% and 18% of total revenue for the quarter and nine months ended September 30, 2017, respectively. A different customer accounted for approximately 11% of total revenue for nine-months ended September 30, 2016. Customers individually accounting for greater than 10% of accounts receivables totaled 28% and 41% of accounts receivables as of September 30, 2017 and December 31, 2016, respectively. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2016-2, Leases (Topic 842) (“ASU 2016-2”). ASU 2016-2 requires that lessees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. The provisions of this guidance are effective for annual periods beginning after December 31, 2018, and for interim periods therein. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2016-2 will have on the Company’s financial statements and which adoption method will be used. In May 2014, the FASB and the International Accounting Standards Board (“IASB”) jointly issued Accounting Standards Update (“ASU”) No. 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”), a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance. The objective of ASU 2014-9 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. An entity can elect to adopt ASU 2014-9 using one of two methods, either full retrospective adoption to each prior reporting period, or recognizing the cumulative effect of adoption at the date of initial application. In March 2016, the FASB issued ASU No. 2016-8, Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net), which clarifies the implementation guidance on principal versus agent considerations. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2014-9 will have on the Company’s financial statements.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Comprehensive Loss	9 Months Ended
Comprehensive Loss	Sep. 30, 2017
Equity [Abstract]
Comprehensive Loss	Comprehensive Loss For the quarters and nine months ended September 30, 2017 and 2016, the Company had no components of other comprehensive income or loss other than net loss itself.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

XML 18 R8.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net Loss Per Common Share



	Quarters Ended September 30,		Nine Months Ended September 30,
	2017	2016	2017	2016
Options	100,237	58,663	98,642	37,709
Warrants	1,206,504	3,525,872	3,469,612	2,621,450
Convertible preferred stock	6,422,034	1,386,888	4,328,089	984,127
Total	7,728,775	4,971,423	7,896,343	3,643,286

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



	September 30, 2017		December 31, 2016
Purchased components	$	914,150	$	466,906
Work in progress	91,335		154,971
Finished goods	780,589		630,361
	$	1,786,074	$	1,252,238

XML 20 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following:



	September 30, 2017		December 31, 2016

Sales return allowance	$	454,730	$	488,200
Technology fees	450,000		450,000
Professional services	343,000		390,800
Advertising and promotion	335,600		28,100
Warranty reserve	112,008		45,879
Other	215,724		245,752
	$	1,911,062	$	1,648,731

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Lease In August 2014, the Company entered into a 5-year operating lease agreement with one 5-year extension option for manufacturing and order fulfillment facilities in Woburn, Massachusetts (the “Woburn Lease”). The Woburn Lease commenced December 15, 2014 and has a monthly base rent of $7,598. In September 2014, the Company entered into a 7-year operating lease agreement with one 5-year extension option for its corporate office and product development activities in Waltham, Massachusetts (the “Waltham Lease”). The term of the Waltham Lease commenced on February 20, 2015 and includes fixed payment obligations that escalate over the initial lease term. Average monthly base rent under the 7-year lease is approximately $37,792. These payment obligations were accrued and recognized over the term of occupancy. Under the Waltham Lease, the landlord was responsible for making certain improvements to the leased space at an agreed upon cost to the landlord. Total costs for the landlord improvements exceeded the agreed upon cost by $275,961. The landlord billed that excess cost to the Company as additional rent which has been included in other long term assets at September 30, 2017. This additional rent has been included in the net calculation of lease payments, so that rent expense is recognized on a straight-line basis over the term of occupancy.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements



			Fair Value Measurements at September 30, 2017 Using
	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	197,370	$	197,370	$	—	$	—
Total	$	197,370	$	197,370	$	—	$	—



	2014 Offering			2013 Offering			Total
Balance at December 31, 2016	$	4,112		$	529		$	4,641
Change in fair value of warrant liability from repricing (see Note 9)	177,999			66,612			244,611
Change in fair value of warrant liability	(147,278		)	(61,202		)	(208,480		)
Repurchase and retirement of warrants (see Note 9)	(34,833		)	(5,939		)	(40,772		)
Balance at September 30, 2017	$	—		$	—		$	—



			Fair Value Measurements at December 31, 2016 Using
	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	833,831	$	833,831	$	—	$	—
Total	$	833,831	$	833,831	$	—	$	—

Liabilities:
Common stock warrants	$	4,641	$	—	$	—	$	4,641
Total	$	4,641	$	—	$	—	$	4,641



	Black-Scholes Inputs to Warrant Liability Valuation at December 31, 2016
Warrants:	Stock Price		Exercise Price		Expected Volatility		Risk-Free Interest		Expected Term	Dividends
2014 Offering	$	5.92	$	65.28	64.19	%	1.33	%	2 years, 6 months	none
2013 Offering	$	5.92	$	64.00	71.61	%	0.99	%	1 year, 5 months	none

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Credit Facility	9 Months Ended
Credit Facility	Sep. 30, 2017
Debt Disclosure [Abstract]
Credit Facility	Credit Facility The Company is party to a Loan and Security Agreement, as amended (the “Credit Facility”), with a bank. As of September 30, 2017, the Credit Facility permitted the Company to borrow up to $2.5 million on a revolving basis. The Credit Facility was amended most recently on December 29, 2016, and expires on January 15, 2018. Amounts borrowed under the Credit Facility will bear interest equal to the prime rate plus 0.5%. Any borrowings under the Credit Facility will be collateralized by the Company’s cash, accounts receivable, inventory, and equipment. The Credit Facility includes traditional lending and reporting covenants. These include certain financial covenants applicable to liquidity that are to be maintained by the Company. As of September 30, 2017, the Company was in compliance with these covenants and had not borrowed any funds under the Credit Facility. However, $226,731 of the amount under the Credit Facility is restricted to support letters of credit issued in favor of the Company's facilities landlords. Consequently, the amount available for borrowing under the Credit Facility as of September 30, 2017 was approximately $2.3 million.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Preferred stock and convertible preferred stock consist of the following:



	September 30, 2017		December 31, 2016
Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2017 and December 31, 2016; no shares issued and outstanding at September 30, 2017 and December 31, 2016	$	—	$	—
Series B convertible preferred stock, $0.001 par value, 147,000 shares designated at September 30, 2017 and December 31, 2016, and 500 shares issued and outstanding at September 30, 2017 and December 31, 2016	$	1	$	1
Series D convertible preferred stock, $0.001 par value, 21,300 shares designated at September 30, 2017 and December 31, 2016, 14,052.93 and 17,202.65 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	14	$	17
Series E convertible preferred stock, $0.001 par value, 7,000 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 7,000 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	7	$	—
Series F convertible preferred stock, $0.001 par value, 10,621 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 5,819.15 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	5	$	—

Private Offerings of Common Stock and Warrants

2017 activity

2016 activity

Other equity activity

Reverse Stock Split

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Reverse Stock Split

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Reverse Stock Split

Stockholders’ Equity

Preferred stock and convertible preferred stock consist of the following:



	September 30, 2017		December 31, 2016
Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2017 and December 31, 2016; no shares issued and outstanding at September 30, 2017 and December 31, 2016	$	—	$	—
Series B convertible preferred stock, $0.001 par value, 147,000 shares designated at September 30, 2017 and December 31, 2016, and 500 shares issued and outstanding at September 30, 2017 and December 31, 2016	$	1	$	1
Series D convertible preferred stock, $0.001 par value, 21,300 shares designated at September 30, 2017 and December 31, 2016, 14,052.93 and 17,202.65 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	14	$	17
Series E convertible preferred stock, $0.001 par value, 7,000 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 7,000 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	7	$	—
Series F convertible preferred stock, $0.001 par value, 10,621 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 5,819.15 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	5	$	—

Private Offerings of Common Stock and Warrants

2017 activity

2016 activity

Other equity activity

Reverse Stock Split

- Definition

+ References

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Business and Basis of Presentation (Policies)	9 Months Ended
Business and Basis of Presentation (Policies)	Sep. 30, 2017
Accounting Policies [Abstract]
Our Business-An Overview	Our Business-An Overview NeuroMetrix, Inc. or the Company, is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The Company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The Company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The Company maintains an active research effort and has several pipeline programs. The Company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. During the first nine months of 2017, the Company completed two equity offerings, detailed in Note 9 to the financial statements, with anticipated gross proceeds of $14.0 million and anticipated net proceeds of approximately $12.9 million after deducting fees and expenses. Gross proceeds of $3.5 million from the second tranche of the Q3 2017 Offering are expected to be received by the Company in October of 2017. The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses from operations and negative cash flows from operating activities. At September 30, 2017, the Company had an accumulated deficit of $188.5 million. The Company held cash and cash equivalents of $4.0 million as of September 30, 2017. The Company believes that these resources, cash proceeds from the second 2017 equity offering, and the cash to be generated from expected product sales will be sufficient to meet its projected operating requirements into the second quarter of 2018. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products and the uncertainty of future revenues; (b) changes the Company may make to the business that affect ongoing operating expenses; (c) changes the Company may make in its business strategy; (d) regulatory developments or inquiries affecting the Company’s existing products and products under development; (e) changes the Company may make in its research and development spending plans; and (f) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company will need to raise additional funds to support its operating and capital needs in the second quarter of 2018 and beyond. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company intends to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected.
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of September 30, 2017, unaudited statements of operations for the quarters and nine months ended September 30, 2017 and 2016 and the unaudited statements of cash flows for the nine months ended September 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2016 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair statement of the Company’s financial position and operating results. Operating results for the quarters and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on February 9, 2017 (File No. 001-33351), or the Company’s 2016 Form 10-K.
Revenues	Revenues The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured. Revenues associated with the Company’s medical devices and consumables are generally recognized upon shipment, assuming all other revenue recognition criteria have been met. Revenue associated with shipments made to distributors who have the right to return any unsold product is recognized once the product is sold by the distributor to the end customer (i.e. under a sell-through model), assuming all other revenue recognition criteria have been met. Cash received prior to all the conditions for revenue recognition being met is recorded as deferred revenue. Deferred revenue recorded prior to cash receipt is recorded as an offset to accounts receivable. As of September 30, 2017 the total value of shipments made to sell-through distributors but not yet sold through to end customers totaled $2,272,736. Of this total, $1,346,942 was recorded as a reduction to accounts receivable and $925,794 was recorded in deferred revenue, as cash had been received. As of December 31, 2016, the total value of shipments that had been made to sell-through distributors but had not yet been sold through to end customers totaled $1,247,545. Of this total, $619,309 was recorded as a reduction to accounts receivable and $628,236 was recorded in deferred revenue, as cash had been received. Related costs of goods sold of $1,466,230 and $910,595 have been deferred and recorded in prepaid expenses and other current assets as of September 30, 2017 and December 31, 2016, respectively. Revenue recognition involves judgments, including assessments of expected returns from customers who have the right to return product for any reason under 30 days or 60 days rights of return. Where the Company can reasonably estimate future returns, it recognizes revenues and records as a reduction of revenue a provision for estimated returns. The Company analyzes various factors, including its historical product returns in arriving at this judgment. Changes in judgments or estimates could materially impact the timing and amount of revenues and costs recognized. The provision for expected returns recorded in accrued expense was $454,730 and $488,200 as of September 30, 2017 and December 31, 2016, respectively. Accounts receivable are recorded net of the allowance for doubtful accounts which represents the Company’s best estimate of probable credit losses. Allowance for doubtful accounts was $25,000 as of September 30, 2017 and December 31, 2016. One customer accounted for 21% and 18% of total revenue for the quarter and nine months ended September 30, 2017, respectively. A different customer accounted for approximately 11% of total revenue for nine-months ended September 30, 2016. Customers individually accounting for greater than 10% of accounts receivables totaled 28% and 41% of accounts receivables as of September 30, 2017 and December 31, 2016, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update No. 2016-2, Leases (Topic 842) (“ASU 2016-2”). ASU 2016-2 requires that lessees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. The provisions of this guidance are effective for annual periods beginning after December 31, 2018, and for interim periods therein. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2016-2 will have on the Company’s financial statements and which adoption method will be used. In May 2014, the FASB and the International Accounting Standards Board (“IASB”) jointly issued Accounting Standards Update (“ASU”) No. 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”), a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance. The objective of ASU 2014-9 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. An entity can elect to adopt ASU 2014-9 using one of two methods, either full retrospective adoption to each prior reporting period, or recognizing the cumulative effect of adoption at the date of initial application. In March 2016, the FASB issued ASU No. 2016-8, Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net), which clarifies the implementation guidance on principal versus agent considerations. The Company is in the process of evaluating the new standard and assessing the impact, if any, ASU 2014-9 will have on the Company’s financial statements.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

in calculating net loss per share amounts, shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:



	Quarters Ended September 30,		Nine Months Ended September 30,
	2017	2016	2017	2016
Options	100,237	58,663	98,642	37,709
Warrants	1,206,504	3,525,872	3,469,612	2,621,450
Convertible preferred stock	6,422,034	1,386,888	4,328,089	984,127
Total	7,728,775	4,971,423	7,896,343	3,643,286

XML 28 R18.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories consist of the following:



	September 30, 2017		December 31, 2016
Purchased components	$	914,150	$	466,906
Work in progress	91,335		154,971
Finished goods	780,589		630,361
	$	1,786,074	$	1,252,238

XML 29 R19.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following:



	September 30, 2017		December 31, 2016

Sales return allowance	$	454,730	$	488,200
Technology fees	450,000		450,000
Professional services	343,000		390,800
Advertising and promotion	335,600		28,100
Warranty reserve	112,008		45,879
Other	215,724		245,752
	$	1,911,062	$	1,648,731

XML 30 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis



			Fair Value Measurements at December 31, 2016 Using
	December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	833,831	$	833,831	$	—	$	—
Total	$	833,831	$	833,831	$	—	$	—

Liabilities:
Common stock warrants	$	4,641	$	—	$	—	$	4,641
Total	$	4,641	$	—	$	—	$	4,641



			Fair Value Measurements at September 30, 2017 Using
	September 30, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	197,370	$	197,370	$	—	$	—
Total	$	197,370	$	197,370	$	—	$	—

Summary of Changes in Fair Value of Company's Level 3 Financial Liabilities



	2014 Offering			2013 Offering			Total
Balance at December 31, 2016	$	4,112		$	529		$	4,641
Change in fair value of warrant liability from repricing (see Note 9)	177,999			66,612			244,611
Change in fair value of warrant liability	(147,278		)	(61,202		)	(208,480		)
Repurchase and retirement of warrants (see Note 9)	(34,833		)	(5,939		)	(40,772		)
Balance at September 30, 2017	$	—		$	—		$	—

Black-Scholes Inputs to Warrant Liability Valuation



	Black-Scholes Inputs to Warrant Liability Valuation at December 31, 2016
Warrants:	Stock Price		Exercise Price		Expected Volatility		Risk-Free Interest		Expected Term	Dividends
2014 Offering	$	5.92	$	65.28	64.19	%	1.33	%	2 years, 6 months	none
2013 Offering	$	5.92	$	64.00	71.61	%	0.99	%	1 year, 5 months	none

XML 31 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Preferred stock and convertible preferred stock

Preferred stock and convertible preferred stock consist of the following:



	September 30, 2017		December 31, 2016
Preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2017 and December 31, 2016; no shares issued and outstanding at September 30, 2017 and December 31, 2016	$	—	$	—
Series B convertible preferred stock, $0.001 par value, 147,000 shares designated at September 30, 2017 and December 31, 2016, and 500 shares issued and outstanding at September 30, 2017 and December 31, 2016	$	1	$	1
Series D convertible preferred stock, $0.001 par value, 21,300 shares designated at September 30, 2017 and December 31, 2016, 14,052.93 and 17,202.65 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	14	$	17
Series E convertible preferred stock, $0.001 par value, 7,000 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 7,000 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	7	$	—
Series F convertible preferred stock, $0.001 par value, 10,621 and zero shares designated at September 30, 2017 and December 31, 2016, respectively, and 5,819.15 and zero shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	$	5	$	—

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

+ Details

XML 32 R22.htm IDEA: XBRL DOCUMENT

Business and Basis of Presentation (Detail)		1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
Business and Basis of Presentation (Detail)	May 12, 2017	Oct. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Organization And Basis Of Presentation [Line Items]
Accumulated deficit			$ 188,457,980	$ 188,457,980		$ 178,478,801
Cash and cash equivalents			3,969,218	3,969,218	$ 7,568,186	3,949,135	$ 12,462,872
Value of shipments made but not yet sold			2,272,736	2,272,736		1,247,545
Reduction to accounts receivable			1,346,942	1,346,942		619,309
Deferred revenue			925,794	925,794		628,236
Deferred costs of goods sold			1,466,230	1,466,230		910,595
Provision for expected returns recorded as accrued expense				454,730		488,200
Allowance for doubtful accounts			$ 25,000	$ 25,000		$ 25,000
Reverse stock split conversion ratio	0.125
Minimum
Organization And Basis Of Presentation [Line Items]
Product sales right of return term				30 days
Maximum
Organization And Basis Of Presentation [Line Items]
Product sales right of return term				60 days
2017 Offerings
Organization And Basis Of Presentation [Line Items]
Gross proceeds from issuance of equity				$ 14,000,000
Net proceeds from issuance of stock and warrants				$ 12,900,000
Customer Concentration Risk \| One Customer \| Revenue
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage			21.00%	18.00%
Customer Concentration Risk \| One Different Customer \| Revenue
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage					11.00%
Customer Concentration Risk \| Two Customers \| Accounts Receivable
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage				28.00%		41.00%
Scenario, Forecast \| Q3 2017 Offering Tranche Two
Organization And Basis Of Presentation [Line Items]
Gross proceeds from issuance of equity		$ 3,500,000

XML 33 R23.htm IDEA: XBRL DOCUMENT

Comprehensive Loss (Detail) - USD ($)	3 Months Ended		9 Months Ended
Comprehensive Loss (Detail) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Equity [Abstract]
Other comprehensive income (loss), net of tax	$ 0	$ 0	$ 0	$ 0

XML 34 R24.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	7,728,775	4,971,423	7,896,343	3,643,286
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	6,422,034	1,386,888	4,328,089	984,127
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	1,206,504	3,525,872	3,469,612	2,621,450
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	100,237	58,663	98,642	37,709

XML 35 R25.htm IDEA: XBRL DOCUMENT

Inventories (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Purchased components	$ 914,150	$ 466,906
Work in progress	91,335	154,971
Finished goods	780,589	630,361
Inventories	$ 1,786,074	$ 1,252,238

XML 36 R26.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Sales return allowance	$ 454,730	$ 488,200
Technology fees	450,000	450,000
Professional services	343,000	390,800
Advertising and promotion	335,600	28,100
Warranty reserve	112,008	45,879
Other	215,724	245,752
Accrued expenses	$ 1,911,062	$ 1,648,731

XML 37 R27.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Detail)			1 Months Ended
Commitments and Contingencies (Detail)	Feb. 20, 2015 USD ($)	Dec. 15, 2014 USD ($)	Sep. 30, 2014 extension_option	Aug. 31, 2014 extension_option	Sep. 30, 2017 USD ($)
5-year operating lease agreement
Operating Leased Assets [Line Items]
Operating lease, term of contract				5 years
Operating lease, number of extension options \| extension_option				1
Operating lease, renewal term				5 years
Monthly base rent		$ 7,598
7-year operating lease agreement
Operating Leased Assets [Line Items]
Operating lease, term of contract	7 years		7 years
Operating lease, number of extension options \| extension_option			1
Operating lease, renewal term			5 years
Monthly base rent	$ 37,792
Excess cost of leasehold improvements					$ 275,961

XML 38 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Liabilities [Abstract]
Common stock warrants		$ 4,641
Fair Value, Measurements, Recurring
Assets
Cash equivalents	$ 197,370	833,831
Total assets measured at fair value on recurring basis	197,370	833,831
Liabilities [Abstract]
Common stock warrants		4,641
Total liabilities measured at fair value on recurring basis		4,641
Fair Value, Measurements, Recurring \| Level 1
Assets
Cash equivalents	197,370	833,831
Total assets measured at fair value on recurring basis	197,370	833,831
Liabilities [Abstract]
Common stock warrants		0
Total liabilities measured at fair value on recurring basis		0
Fair Value, Measurements, Recurring \| Level 2
Assets
Cash equivalents	0	0
Total assets measured at fair value on recurring basis	0	0
Liabilities [Abstract]
Common stock warrants		0
Total liabilities measured at fair value on recurring basis		0
Fair Value, Measurements, Recurring \| Level 3
Assets
Cash equivalents	0	0
Total assets measured at fair value on recurring basis	$ 0	0
Liabilities [Abstract]
Common stock warrants		4,641
Total liabilities measured at fair value on recurring basis		$ 4,641

XML 39 R29.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Liabilities (Detail) (Details)	9 Months Ended
	Sep. 30, 2017 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Repurchase and retirement of warrants	$ (40,772)
2014 Offering
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Repurchase and retirement of warrants	(34,833)
2013 Offering
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Repurchase and retirement of warrants	(5,939)
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	4,641
Change in fair value of warrant liability from repricing	244,611
Change in fair value of warrant liability	(208,480)
Ending Balance	0
Warrants \| 2014 Offering
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	4,112
Change in fair value of warrant liability from repricing	177,999
Change in fair value of warrant liability	(147,278)
Ending Balance	0
Warrants \| 2013 Offering
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	529
Change in fair value of warrant liability from repricing	66,612
Change in fair value of warrant liability	(61,202)
Ending Balance	$ 0

XML 40 R30.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2016 USD ($)
Fair Value Disclosures [Abstract]
Common stock warrants liability	$ 4,641

XML 41 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Black-Scholes Inputs to Warrant Liability Valuation (Details)	12 Months Ended
	Dec. 31, 2016 $ / shares
2014 Offering
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Price (in dollars per share)	$ 5.92
Exercise Price (in dollars per share)	$ 65.28
Expected Volatility	64.19%
Risk-Free Interest	1.33%
Expected Term	2 years 6 months
Dividends	0.00%
2013 Offering
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Price (in dollars per share)	$ 5.92
Exercise Price (in dollars per share)	$ 64.00
Expected Volatility	71.61%
Risk-Free Interest	0.99%
Expected Term	1 year 5 months
Dividends	0.00%

XML 42 R32.htm IDEA: XBRL DOCUMENT

Credit Facility (Detail)	9 Months Ended
Credit Facility (Detail)	Sep. 30, 2017 USD ($)
Line of Credit Facility [Line Items]
Revolving credit facility, maximum borrowing capacity	$ 2,500,000
Credit facility expiration date	Jan. 15, 2018
Credit facility limit restricted to support letter of credit	$ 226,731
Line of credit facility, remaining borrowing capacity	$ 2,300,000
Prime Rate
Line of Credit Facility [Line Items]
Interest rate over prime rate	0.50%

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Preferred Stock and Convertible Preferred Stock (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Non-Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 0	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 1	$ 1
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	500	500
Preferred stock, shares outstanding (in shares)	500	500
Preferred stock, shares designated (in shares)	147,000	147,000
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 14	$ 17
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	14,052.93	17,202.65
Preferred stock, shares outstanding (in shares)	14,052.93	17,202.65
Preferred stock, shares designated (in shares)	21,300	21,300
Series E Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 7	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	7,000	0
Preferred stock, shares outstanding (in shares)	7,000	0
Preferred stock, shares designated (in shares)	7,000	0
Series F Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 5	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	5,819.15	0
Preferred stock, shares outstanding (in shares)	5,819.15	0
Preferred stock, shares designated (in shares)	10,621	0

XML 44 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001		$ 0.0001	$ 0.0001
Compensation cost not yet recognized		$ 418,881		$ 418,881
Compensation cost not yet recognized, period for recognition				2 years 7 months 6 days
Series F Preferred Stock
Class of Stock [Line Items]
Shares converted (in shares)				(1,301.85)
Convertible preferred stock, shares issued upon conversion (in shares)		(495,000)		(495,000)
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)		14,052.93		14,052.93	17,202.65
Series E Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)		7,000		7,000	0
Series D Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)		14,052.93		14,052.93
Shares converted (in shares)				3,149.72
Series F Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)		5,819.15		5,819.15	0
2017 Offering
Class of Stock [Line Items]
Net proceeds from issuance of stock and warrants			$ 6,300,000
Net proceeds from issuance of stock and warrants			$ 7,000,000
2017 Offering \| Series D Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)			19,458.90
2017 Offering \| Series E Convertible Preferred Stock
Class of Stock [Line Items]
Shares issued during period (in shares)			7,000
Q3 2017 Offering \| Series D Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)		14,052.93		14,052.93
Q3 2017 Offering \| Series E Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)		7,000		7,000
Q3 2017 Offering \| Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock, conversion price (in dollars per share)				$ 2.63
Dividends, preferred stock, total		$ 2,800,000
Q3 2017 Offering Tranche One
Class of Stock [Line Items]
Gross proceeds from issuance of equity		3,500,000
Net proceeds from issuance of stock and warrants		$ 3,300,000
Q3 2017 Offering Tranche One \| Series F Preferred Stock
Class of Stock [Line Items]
Shares issued during period (in shares)		3,500
Shares issued (in dollars per share)		$ 1,000		$ 1,000
Shares of common stock available to purchase (in shares)		3,621		3,621
Number of shares authorized to be repurchased (in shares)		4,184,483		4,184,483
Gross proceeds from issuance of equity		$ 3,622,219
Q3 2017 Offering Tranche Two \| Series F Preferred Stock
Class of Stock [Line Items]
Shares issued during period (in shares)		3,500
Shares issued (in dollars per share)		$ 1,000		$ 1,000
Q1 2017 Offering \| Series E Convertible Preferred Stock
Class of Stock [Line Items]
Shares issued (in dollars per share)			$ 1,000
Q1 2017 Offering \| Preferred Stock
Class of Stock [Line Items]
Dividends, preferred stock, total			$ 4,000,000
2017 Offerings
Class of Stock [Line Items]
Gross proceeds from issuance of equity				$ 14,000,000
Net proceeds from issuance of stock and warrants				$ 12,900,000
2017 Offerings \| Preferred Stock
Class of Stock [Line Items]
Shares issued (in dollars per share)		$ 1,000		$ 1,000
Convertible preferred stock, conversion price (in dollars per share)				$ 2.63
June 2016 Offering
Class of Stock [Line Items]
Net proceeds from issuance of stock and warrants	$ 6,700,000
Net proceeds from issuance of stock and warrants	$ 7,500,000
June 2016 Offering \| Series D Preferred Stock
Class of Stock [Line Items]
Shares issued (in dollars per share)	$ 1,000
Shares issued during period (in shares)	21,300
June 2016 Offering \| Series C Preferred Stock
Class of Stock [Line Items]
Dividends, preferred stock, total	$ 19,800,000
Shares redeemed during period (in shares)	13,800
Common Stock
Class of Stock [Line Items]
Convertible preferred stock, shares issued upon conversion (in shares)		(809,103)		(809,103)
Common Stock \| 2017 Offering
Class of Stock [Line Items]
Shares of common stock available to purchase (in shares)			1,250,000
Common stock, par value (in dollars per share)			$ 0.0001
Number of securities available to purchase by warrants or rights			2,934,484
Common Stock \| June 2016 Offering
Class of Stock [Line Items]
Shares of common stock available to purchase (in shares)	1,475,069
Common stock, par value (in dollars per share)	$ 0.0001
Exercise price of warrants or rights (in dollars per share)	$ 13.52
Warrants \| 2017 Offering
Class of Stock [Line Items]
Exercise price of warrants or rights (in dollars per share)			$ 5.6
Warrants \| Q1 2017 Offering
Class of Stock [Line Items]
Exercise price of warrants or rights (in dollars per share)			$ 5.60
Class of warrant exercisable period			5 years
Warrants not settleable in cash, fair value disclosure			$ 3,490,000
Exercise price (in dollars per share)			$ 4.96
Expected volatility			70.20%
Risk free interest rate			2.04%
Expected term			5 years
Expected dividends			0.00%

XML 45 R35.htm IDEA: XBRL DOCUMENT

Reverse Stock Split (Details)	May 12, 2017 shares	Sep. 30, 2017 shares	May 11, 2017 shares	Dec. 31, 2016 shares
Class of Stock [Line Items]
Shares outstanding (in shares)	1,268,440	2,145,519	10,147,721	836,862
Reverse stock split conversion ratio	0.125

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

A._,W?APZKOI/Y]M[Y^^;5&N MT[>QGEGR>)7@4G*O*!B%NDE2W_[-!+(F<(H7RWC-QPLV7DSQ7]:-:/)GY$%OC1I!W,).2+4;CZH3K04EL$WH]A M_1CJ!P(_AK1C$3-M EU!=499/\T$[\>R?BSU$RRX1TMG#_A9$71C065*H,DB M:RMGW>34C0C+:86"_S4 5*51%2%2@O(0?(--FQ&*&6UHB8)QZM0-DJ0K8"A6:. MRN1DW*A.HT416:W PQ4H765(5Z#8E*A4!F3@J% (L-+&//& !4I8&1(6*#I# MFC$2J65LP'BV H6K#.$*#%WY[J%"(5# XO!Q[XDG+%#$RA"QG(9,H \U]\

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end XML 47 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 105 157 1 false 40 0 false 5 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://neurometrix.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - Balance Sheets Sheet http://neurometrix.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Balance Sheets (Unaudited) (Parenthetical) Sheet http://neurometrix.com/role/BalanceSheetsUnauditedParenthetical Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Statements of Operations (Unaudited) Sheet http://neurometrix.com/role/StatementsOfOperationsUnaudited Statements of Operations (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Statements of Cash Flows (Unaudited) Sheet http://neurometrix.com/role/StatementsOfCashFlowsUnaudited Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 2101100 - Disclosure - Business and Basis of Presentation Sheet http://neurometrix.com/role/BusinessAndBasisOfPresentation Business and Basis of Presentation Notes 6 false false R7.htm 2102100 - Disclosure - Comprehensive Loss Sheet http://neurometrix.com/role/ComprehensiveLoss Comprehensive Loss Notes 7 false false R8.htm 2103100 - Disclosure - Net Loss Per Common Share Sheet http://neurometrix.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 8 false false R9.htm 2106100 - Disclosure - Inventories Sheet http://neurometrix.com/role/Inventories Inventories Notes 9 false false R10.htm 2107100 - Disclosure - Accrued Expenses Sheet http://neurometrix.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 2108100 - Disclosure - Commitments and Contingencies Sheet http://neurometrix.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 2111100 - Disclosure - Fair Value Measurements Sheet http://neurometrix.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2112100 - Disclosure - Credit Facility Sheet http://neurometrix.com/role/CreditFacility Credit Facility Notes 13 false false R14.htm 2113100 - Disclosure - Stockholders' Equity Sheet http://neurometrix.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 2114100 - Disclosure - Reverse Stock Split Sheet http://neurometrix.com/role/ReverseStockSplit Reverse Stock Split Notes 15 false false R16.htm 2201201 - Disclosure - Business and Basis of Presentation (Policies) Sheet http://neurometrix.com/role/BusinessAndBasisOfPresentationPolicies Business and Basis of Presentation (Policies) Policies 16 false false R17.htm 2303301 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://neurometrix.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://neurometrix.com/role/NetLossPerCommonShare 17 false false R18.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://neurometrix.com/role/InventoriesTables Inventories (Tables) Tables http://neurometrix.com/role/Inventories 18 false false R19.htm 2307301 - Disclosure - Accrued Expenses (Tables) Sheet http://neurometrix.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://neurometrix.com/role/AccruedExpenses 19 false false R20.htm 2311301 - Disclosure - Fair Value Measurements (Tables) Sheet http://neurometrix.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://neurometrix.com/role/FairValueMeasurements 20 false false R21.htm 2313301 - Disclosure - Stockholders' Equity (Tables) Sheet http://neurometrix.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://neurometrix.com/role/StockholdersEquity 21 false false R22.htm 2401402 - Disclosure - Business and Basis of Presentation (Detail) Sheet http://neurometrix.com/role/BusinessAndBasisOfPresentationDetail Business and Basis of Presentation (Detail) Details http://neurometrix.com/role/BusinessAndBasisOfPresentationPolicies 22 false false R23.htm 2402401 - Disclosure - Comprehensive Loss (Detail) Sheet http://neurometrix.com/role/ComprehensiveLossDetail Comprehensive Loss (Detail) Details http://neurometrix.com/role/ComprehensiveLoss 23 false false R24.htm 2403402 - Disclosure - Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Sheet http://neurometrix.com/role/NetLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Details 24 false false R25.htm 2406402 - Disclosure - Inventories (Detail) Sheet http://neurometrix.com/role/InventoriesDetail Inventories (Detail) Details http://neurometrix.com/role/InventoriesTables 25 false false R26.htm 2407402 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://neurometrix.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 26 false false R27.htm 2408401 - Disclosure - Commitments and Contingencies (Detail) Sheet http://neurometrix.com/role/CommitmentsAndContingenciesDetail Commitments and Contingencies (Detail) Details http://neurometrix.com/role/CommitmentsAndContingencies 27 false false R28.htm 2411402 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://neurometrix.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 28 false false R29.htm 2411403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Liabilities (Detail) (Details) Sheet http://neurometrix.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfCompanysLevel3FinancialLiabilitiesDetailDetails Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Liabilities (Detail) (Details) Details 29 false false R30.htm 2411404 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://neurometrix.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 30 false false R31.htm 2411405 - Disclosure - Fair Value Measurements - Black-Scholes Inputs to Warrant Liability Valuation (Details) Sheet http://neurometrix.com/role/FairValueMeasurementsBlackScholesInputsToWarrantLiabilityValuationDetails Fair Value Measurements - Black-Scholes Inputs to Warrant Liability Valuation (Details) Details 31 false false R32.htm 2412401 - Disclosure - Credit Facility (Detail) Sheet http://neurometrix.com/role/CreditFacilityDetail Credit Facility (Detail) Details http://neurometrix.com/role/CreditFacility 32 false false R33.htm 2413402 - Disclosure - Stockholders' Equity - Preferred Stock and Convertible Preferred Stock (Detail) Sheet http://neurometrix.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetail Stockholders' Equity - Preferred Stock and Convertible Preferred Stock (Detail) Details 33 false false R34.htm 2413403 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://neurometrix.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 34 false false R35.htm 2414401 - Disclosure - Reverse Stock Split (Details) Sheet http://neurometrix.com/role/ReverseStockSplitDetails Reverse Stock Split (Details) Details http://neurometrix.com/role/ReverseStockSplit 35 false false All Reports Book All Reports nuro-20170930.xml nuro-20170930.xsd nuro-20170930_cal.xml nuro-20170930_def.xml nuro-20170930_lab.xml nuro-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2016-01-31 true true ZIP 52 0001628280-17-010010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-17-010010-xbrl.zip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